WO2024102621A1 - Modulateurs de akt1 - Google Patents

Modulateurs de akt1 Download PDF

Info

Publication number
WO2024102621A1
WO2024102621A1 PCT/US2023/078714 US2023078714W WO2024102621A1 WO 2024102621 A1 WO2024102621 A1 WO 2024102621A1 US 2023078714 W US2023078714 W US 2023078714W WO 2024102621 A1 WO2024102621 A1 WO 2024102621A1
Authority
WO
WIPO (PCT)
Prior art keywords
optionally substituted
pharmaceutically acceptable
pyridin
solvate
compound
Prior art date
Application number
PCT/US2023/078714
Other languages
English (en)
Inventor
Michael David Bartberger
Yi Fan
Eric Anthony MURPHY
Xuefeng Zhu
Original Assignee
Alterome Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Alterome Therapeutics, Inc. filed Critical Alterome Therapeutics, Inc.
Publication of WO2024102621A1 publication Critical patent/WO2024102621A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Definitions

  • AKT is a protein kinase and mediates cell survival and proliferation by inhibiting pathways which promotes apoptosis.
  • AKT signaling cascade dysfunction is observed in several cancer types and may be associated with tumor aggressiveness. Additionally, malfunction of AKT typically lead to enhanced proliferation, growth, survival, and resistance to apoptosis.
  • Pharmaceutical agents with the ability to modulate AKT1 activity would be useful in the treatment of disease, such as cancer.
  • One embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; X is -C(O)-, or -S(O)2-; R 1 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted C3-C10 carbocyclyl, or optionally substituted heteroaryl; R 3 is selected
  • One embodiment provides a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof: WSGR Docket No.62619-716.601 wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; R 1 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 3 is selected from halogen, -CN, optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 4 is selected from halogen, -CN, optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 5 and R 6 are each independently hydrogen, deuterium
  • One embodiment provides a pharmaceutical composition comprising a compound of Formula (I), or pharmaceutically acceptable salt or solvate thereof, and at least one pharmaceutically acceptable excipient.
  • One embodiment provides a method of treating a disease or disorder in a patient in need thereof comprising administering to the patient a compound of Formula (I), or pharmaceutically acceptable salt or solvate thereof. Another embodiment provides the method wherein the disease or disorder is cancer. INCORPORATION BY REFERENCE [008] All publications, patents, and patent applications mentioned in this specification are herein incorporated by reference for the specific purposes identified herein.
  • Alkyl refers to a straight or branched hydrocarbon chain radical consisting solely of carbon and hydrogen atoms, containing no unsaturation, having from one to fifteen carbon atoms (e.g., C1-C15 alkyl). In certain embodiments, an alkyl comprises one to thirteen carbon atoms (e.g., C1-C13 alkyl). In certain embodiments, an alkyl comprises one to eight carbon atoms (e.g., C 1 -C 8 alkyl).
  • an alkyl comprises one to five carbon atoms (e.g., C1-C5 alkyl). In other embodiments, an alkyl comprises one to four carbon atoms (e.g., C1- C4 alkyl). In other embodiments, an alkyl comprises one to three carbon atoms (e.g., C1-C3 alkyl). In other embodiments, an alkyl comprises one to two carbon atoms (e.g., C 1 -C 2 alkyl). In other embodiments, an alkyl comprises one carbon atom (e.g., C1 alkyl). In other embodiments, an alkyl comprises five to fifteen carbon atoms (e.g., C5-C15 alkyl).
  • an alkyl comprises five to eight carbon atoms (e.g., C 5 -C 8 alkyl). In other embodiments, an alkyl comprises two to five carbon atoms (e.g., C2-C5 alkyl). In other embodiments, an alkyl comprises three to five carbon atoms (e.g., C3-C5 alkyl).
  • the alkyl group is selected from methyl, ethyl, 1-propyl (n-propyl), 1-methylethyl (iso-propyl), 1-butyl (n-butyl), 1-methylpropyl (sec-butyl), 2-methylpropyl (iso-butyl), 1,1-dimethylethyl (tert-butyl), 1-pentyl (n-pentyl).
  • the alkyl is attached to the rest of the molecule by a single bond.
  • an alkyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, - N(R a )C(O)OR a , -OC(O)-N(R a ) 2 , -N(R a )C(O)R a , -N(R a )S(O) t R a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O)tR a (where t is 1 or 2), -S(
  • an optionally substituted alkyl is a haloalkyl. In other embodiments, an optionally substituted alkyl is a fluoroalkyl. In other embodiments, an optionally substituted alkyl is a -CF3 group.
  • Alkoxy refers to a radical bonded through an oxygen atom of the formula –O-alkyl, where alkyl is an alkyl chain as defined above.
  • Alkenyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms.
  • an alkenyl comprises two to eight carbon atoms. In other embodiments, an alkenyl comprises two to four carbon atoms.
  • the alkenyl is attached to the rest of the molecule by a single bond, for example, ethenyl (i.e., vinyl), prop-1-enyl (i.e., allyl), but-1-enyl, pent-1-enyl, penta-1,4-dienyl, and the like.
  • an alkenyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, - N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S(O)t
  • Alkynyl refers to a straight or branched hydrocarbon chain radical group consisting solely of carbon and hydrogen atoms, containing at least one carbon-carbon triple bond, having WSGR Docket No.62619-716.601 from two to twelve carbon atoms.
  • an alkynyl comprises two to eight carbon atoms.
  • an alkynyl comprises two to six carbon atoms.
  • an alkynyl comprises two to four carbon atoms.
  • alkynyl is attached to the rest of the molecule by a single bond, for example, ethynyl, propynyl, butynyl, pentynyl, hexynyl, and the like.
  • an alkynyl group is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , - C(O)N(R a ) 2 , -N(R a )C(O)OR a , -OC(O)-N(R a ) 2 , -N(R a )C(O)OR a , -
  • Alkylene or "alkylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing no unsaturation, and having from one to twelve carbon atoms, for example, methylene, ethylene, propylene, n-butylene, and the like.
  • the alkylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • the points of attachment of the alkylene chain to the rest of the molecule and to the radical group are through one carbon in the alkylene chain or through any two carbons within the chain.
  • an alkylene comprises one to eight carbon atoms (e.g., C1-C8 alkylene). In other embodiments, an alkylene comprises one to five carbon atoms (e.g., C 1 -C 5 alkylene). In other embodiments, an alkylene comprises one to four carbon atoms (e.g., C1-C4 alkylene). In other embodiments, an alkylene comprises one to three carbon atoms (e.g., C1-C3 alkylene). In other embodiments, an alkylene comprises one to two carbon atoms (e.g., C 1 -C 2 alkylene). In other embodiments, an alkylene comprises one carbon atom (e.g., C 1 alkylene).
  • an alkylene comprises five to eight carbon atoms (e.g., C5-C8 alkylene). In other embodiments, an alkylene comprises two to five carbon atoms (e.g., C2-C5 alkylene). In other embodiments, an alkylene comprises three to five carbon atoms (e.g., C 3 -C 5 WSGR Docket No.62619-716.601 alkylene).
  • an alkylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a ) 2 , -C(O)R a , -C(O)OR a , - C(O)N(R a )2, -N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O) t OR a (where t is 1 or 2), -S(O) t R a (where t is
  • alkenylene or "alkenylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon double bond, and having from two to twelve carbon atoms.
  • the alkenylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • an alkenylene comprises two to eight carbon atoms (e.g., C2-C8 alkenylene).
  • an alkenylene comprises two to five carbon atoms (e.g., C2-C5 alkenylene).
  • an alkenylene comprises two to four carbon atoms (e.g., C 2 -C 4 alkenylene). In other embodiments, an alkenylene comprises two to three carbon atoms (e.g., C2-C3 alkenylene). In other embodiments, an alkenylene comprises two carbon atoms (e.g., C2 alkenylene). In other embodiments, an alkenylene comprises five to eight carbon atoms (e.g., C 5 -C 8 alkenylene). In other embodiments, an alkenylene comprises three to five carbon atoms (e.g., C3-C5 alkenylene).
  • an alkenylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , -C(O)N(R a )2, - N(R a )C(O)OR a , -OC(O)-N(R a )2, -N(R a )C(O)R a , -N(R a )S(O)tR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S(O)t
  • Alkynylene or “alkynylene chain” refers to a straight or branched divalent hydrocarbon chain linking the rest of the molecule to a radical group, consisting solely of carbon and hydrogen, containing at least one carbon-carbon triple bond, and having from two to twelve carbon atoms.
  • the alkynylene chain is attached to the rest of the molecule through a single bond and to the radical group through a single bond.
  • an alkynylene comprises two to eight carbon atoms (e.g., C2-C8 alkynylene).
  • an alkynylene comprises two to five carbon atoms (e.g., C 2 -C 5 alkynylene).
  • an alkynylene comprises two to four carbon atoms (e.g., C2-C4 alkynylene). In other embodiments, an alkynylene comprises two to three carbon atoms (e.g., C2-C3 alkynylene). In other embodiments, an alkynylene comprises two carbon atoms (e.g., C 2 alkynylene). In other embodiments, an alkynylene comprises five to eight carbon atoms (e.g., C5-C8 alkynylene). In other embodiments, an alkynylene comprises three to five carbon atoms (e.g., C3-C5 alkynylene).
  • an alkynylene chain is optionally substituted by one or more of the following substituents: halo, cyano, nitro, oxo, thioxo, imino, oximo, trimethylsilanyl, -OR a , -SR a , -OC(O)-R a , -N(R a )2, -C(O)R a , -C(O)OR a , - C(O)N(R a ) 2 , -N(R a )C(O)OR a , -OC(O)-N(R a ) 2 , -N(R a )C(O)R a , -N(R a )S(O) t R a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2), -S(O)tOR a (where t is 1 or 2),
  • Aryl refers to a radical derived from an aromatic monocyclic or multicyclic hydrocarbon ring system by removing a hydrogen atom from a ring carbon atom.
  • the aromatic monocyclic or multicyclic hydrocarbon ring system contains only hydrogen and carbon from five to eighteen carbon atoms, where at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) p–electron system in accordance with the Hückel theory.
  • aryl groups include, but are not limited to, groups such as benzene, fluorene, indane, indene, tetralin and naphthalene.
  • aryl or the prefix "ar-" is meant to include aryl radicals optionally substituted by one or more substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b - OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b -C(O)R a , -R b -C(O)R a , -R
  • Aralkyl refers to a radical of the formula -R c -aryl where R c is an alkylene chain as defined above, for example, methylene, ethylene, and the like.
  • the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
  • the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
  • “Aralkenyl” refers to a radical of the formula –R d -aryl where R d is an alkenylene chain as defined above.
  • the aryl part of the aralkenyl radical is optionally substituted as described above for an aryl group.
  • alkenylene chain part of the aralkenyl radical is optionally substituted as defined above for an alkenylene group.
  • WSGR Docket No.62619-716.601 "Aralkynyl” refers to a radical of the formula -R e -aryl, where R e is an alkynylene chain as defined above.
  • the aryl part of the aralkynyl radical is optionally substituted as described above for an aryl group.
  • the alkynylene chain part of the aralkynyl radical is optionally substituted as defined above for an alkynylene chain.
  • Alkoxy refers to a radical bonded through an oxygen atom of the formula -O-R c -aryl where R c is an alkylene chain as defined above, for example, methylene, ethylene, and the like.
  • the alkylene chain part of the aralkyl radical is optionally substituted as described above for an alkylene chain.
  • the aryl part of the aralkyl radical is optionally substituted as described above for an aryl group.
  • Carbocyclyl refers to a stable non-aromatic monocyclic or polycyclic hydrocarbon radical consisting solely of carbon and hydrogen atoms, which includes fused or bridged ring systems, having from three to fifteen carbon atoms.
  • a carbocyclyl comprises three to ten carbon atoms. In other embodiments, a carbocyclyl comprises five to seven carbon atoms. The carbocyclyl is attached to the rest of the molecule by a single bond. Carbocyclyl is saturated (i.e., containing single C-C bonds only) or unsaturated (i.e., containing one or more double bonds or triple bonds).
  • a fully saturated carbocyclyl radical is also referred to as "cycloalkyl.”
  • monocyclic cycloalkyls include, e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl.
  • An unsaturated carbocyclyl is also referred to as "cycloalkenyl.”
  • Examples of monocyclic cycloalkenyls include, e.g., cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl.
  • Polycyclic carbocyclyl radicals include, for example, adamantyl, norbornyl (i.e., bicyclo[2.2.1]heptanyl), norbornenyl, decalinyl, 7,7-dimethyl-bicyclo[2.2.1]heptanyl, and the like.
  • carbocyclyl is meant to include carbocyclyl radicals that are optionally substituted by one or more substituents independently selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, oxo, thioxo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a ) 2 , -R b - N(R a )2, -R b -C(O)R a , -R b -C(O)OR a , -R b -C(O)N(R a )2, -R b -O-R c -C(O)N(R a )2,
  • Carbocyclylalkyl refers to a radical of the formula –R c -carbocyclyl where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
  • Carbocyclylalkynyl refers to a radical of the formula –R c -carbocyclyl where R c is an alkynylene chain as defined above. The alkynylene chain and the carbocyclyl radical is optionally substituted as defined above.
  • Carbocyclylalkoxy refers to a radical bonded through an oxygen atom of the formula – O-R c -carbocyclyl where R c is an alkylene chain as defined above. The alkylene chain and the carbocyclyl radical is optionally substituted as defined above.
  • Halo or “halogen” refers to bromo, chloro, fluoro or iodo substituents.
  • Fluoroalkyl refers to an alkyl radical, as defined above, that is substituted by one or more fluoro radicals, as defined above, for example, trifluoromethyl, difluoromethyl, fluoromethyl, 2,2,2-trifluoroethyl, 1-fluoromethyl-2-fluoroethyl, and the like.
  • the alkyl part of the fluoroalkyl radical is optionally substituted as defined above for an alkyl group.
  • Heterocyclyl refers to a stable 3- to 18-membered non-aromatic ring radical that comprises two to twelve carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen and sulfur.
  • the heterocyclyl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which optionally includes fused or bridged ring systems.
  • the heteroatoms in the heterocyclyl radical are optionally oxidized.
  • One or more nitrogen atoms, if present, are optionally quaternized.
  • the heterocyclyl radical is partially or fully saturated.
  • the heterocyclyl is attached to the rest of the molecule through any atom of the ring(s).
  • heterocyclyl radicals include, but are not limited to, dioxolanyl, thienyl[1,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thio
  • heterocyclyl is meant to include heterocyclyl radicals as defined above that are optionally substituted by one or more substituents selected from optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, fluoroalkyl, oxo, thioxo, cyano, nitro, - R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , -R b -OC(O)-N(R a )2, -R b -N(R a )2, -R b -C(O)R a , -R b - C(O)OR a , -R b -C(O)N(R a ) 2 , -R
  • N-heterocyclyl or “N-attached heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one nitrogen and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a nitrogen atom in the heterocyclyl radical.
  • An N-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals. Examples of such N-heterocyclyl radicals include, but are not limited to, 1-morpholinyl, 1- piperidinyl, 1-piperazinyl, 1-pyrrolidinyl, pyrazolidinyl, and imidazolidinyl.
  • C-heterocyclyl or “C-attached heterocyclyl” refers to a heterocyclyl radical as defined above containing at least one heteroatom and where the point of attachment of the heterocyclyl radical to the rest of the molecule is through a carbon atom in the heterocyclyl radical.
  • a C-heterocyclyl radical is optionally substituted as described above for heterocyclyl radicals. Examples of such C-heterocyclyl radicals include, but are not limited to, 2-morpholinyl, 2- or 3- or 4-piperidinyl, 2-piperazinyl, 2- or 3-pyrrolidinyl, and the like.
  • Heterocyclylalkyl refers to a radical of the formula –R c -heterocyclyl where R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom. The alkylene chain of the heterocyclylalkyl radical is optionally substituted as defined above for an alkylene chain. WSGR Docket No.62619-716.601 The heterocyclyl part of the heterocyclylalkyl radical is optionally substituted as defined above for a heterocyclyl group.
  • Heterocyclylalkoxy refers to a radical bonded through an oxygen atom of the formula –O-R c -heterocyclyl where R c is an alkylene chain as defined above. If the heterocyclyl is a nitrogen-containing heterocyclyl, the heterocyclyl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heterocyclylalkoxy radical is optionally substituted as defined above for an alkylene chain.
  • the heterocyclyl part of the heterocyclylalkoxy radical is optionally substituted as defined above for a heterocyclyl group.
  • Heteroaryl refers to a radical derived from a 3 to 18 membered aromatic ring radical that comprises two to seventeen carbon atoms and from one to six heteroatoms selected from nitrogen, oxygen, and sulfur.
  • the heteroaryl radical is a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, wherein at least one of the rings in the ring system is fully unsaturated, i.e., it contains a cyclic, delocalized (4n+2) p–electron system in accordance with the Hückel theory.
  • Heteroaryl includes fused or bridged ring systems.
  • the heteroatom(s) in the heteroaryl radical is optionally oxidized.
  • heteroaryl is attached to the rest of the molecule through any atom of the ring(s).
  • heteroaryls include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzindolyl, 1,3benzodioxolyl, benzofuranyl, benzooxazolyl, benzo[d]thiazolyl, benzothiadiazolyl, benzo[b][1,4]dioxepinyl, benzo[b][1,4]oxazinyl, 1,4benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodioxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophen
  • heteroaryl is meant to include heteroaryl radicals as defined above which are optionally substituted by one or more substituents selected from optionally substituted alkyl, optionally substituted cycloalkylalkyl, optionally substituted heterocyclylalkyl, optionally substituted alkenyl, optionally substituted alkynyl, halo, optionally substituted fluoroalkyl, optionally substituted haloalkenyl, optionally substituted haloalkynyl, oxo, thioxo, cyano, nitro, -R b -OR a , -R b -OC(O)-R a , -R b -OC(O)-OR a , - R b -OC(O)-N(R a ) 2 , -R b -N(R a ) 2 , -R b -C
  • N-heteroaryl refers to a heteroaryl radical as defined above containing at least one nitrogen and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a nitrogen atom in the heteroaryl radical.
  • An N-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
  • C-heteroaryl refers to a heteroaryl radical as defined above and where the point of attachment of the heteroaryl radical to the rest of the molecule is through a carbon atom in the heteroaryl radical.
  • a C-heteroaryl radical is optionally substituted as described above for heteroaryl radicals.
  • Heteroarylalkyl refers to a radical of the formula –R c heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen-containing heteroaryl, the WSGR Docket No.62619-716.601 heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heteroarylalkyl radical is optionally substituted as defined above for an alkylene chain.
  • the heteroaryl part of the heteroarylalkyl radical is optionally substituted as defined above for a heteroaryl group.
  • Heteroarylalkoxy refers to a radical bonded through an oxygen atom of the formula – O-R c heteroaryl, where R c is an alkylene chain as defined above. If the heteroaryl is a nitrogen- containing heteroaryl, the heteroaryl is optionally attached to the alkyl radical at the nitrogen atom.
  • the alkylene chain of the heteroarylalkoxy radical is optionally substituted as defined above for an alkylene chain.
  • the heteroaryl part of the heteroarylalkoxy radical is optionally substituted as defined above for a heteroaryl group.
  • the compounds disclosed herein in some embodiments, contain one or more asymmetric centers and thus give rise to enantiomers, diastereomers, and other stereoisomeric forms that are defined, in terms of absolute stereochemistry, as (R)- or (S)-. Unless stated otherwise, it is intended that all stereoisomeric forms of the compounds disclosed herein are contemplated by this disclosure. When the compounds described herein contain alkene double bonds, and unless specified otherwise, it is intended that this disclosure includes both E and Z geometric isomers (e.g., cis or trans.) Likewise, all possible isomers, as well as their racemic and optically pure forms, and all tautomeric forms are also intended to be included.
  • geometric isomer refers to E or Z geometric isomers (e.g., cis or trans) of an alkene double bond.
  • positional isomer refers to structural isomers around a central ring, such as ortho-, meta-, and para- isomers around a benzene ring.
  • carboxylic acid bioisostere refers to a functional group or moiety that exhibits similar physical, biological and/or chemical properties as a carboxylic acid moiety.
  • Examples of carboxylic acid bioisosteres include, but are not limited to, [0050]
  • a "tautomer” refers to a molecule wherein a proton shift from one atom of a molecule to another atom of the same molecule is possible.
  • tautomeric equilibrium include: [0051]
  • the compounds disclosed herein, in some embodiments, are used in different enriched isotopic forms, e.g., enriched in the content of 2 H, 3 H, 11 C, 13 C and/or 14 C.
  • the compound is deuterated in at least one position.
  • deuterated forms can be made by the procedure described in U.S. Patent Nos.5,846,514 and 6,334,997.
  • deuteration can improve the metabolic stability and or efficacy, thus increasing the duration of action of drugs.
  • structures depicted herein are intended to include compounds which differ only in the presence of one or more isotopically enriched atoms.
  • compounds having the present structures except for the replacement of a hydrogen by a deuterium or tritium, or the replacement of a carbon by 13 C- or 14 C-enriched carbon are within the scope of the present disclosure.
  • the compounds of the present disclosure optionally contain unnatural proportions of atomic isotopes at one or more atoms that constitute such compounds.
  • the compounds may be labeled with isotopes, such as for example, deuterium ( 2 H), tritium ( 3 H), iodine-125 ( 125 I) or carbon-14 ( 14 C).
  • deuterium substituted compounds are synthesized using various methods such as described in: Dean, Dennis C.; Editor. Recent Advances in the Synthesis and Applications of Radiolabeled Compounds for Drug Discovery and Development. [Curr., Pharm. Des., 2000; 6(10)] 2000, 110 pp; George W.; Varma, Rajender S. The Synthesis of Radiolabeled Compounds via Organometallic Intermediates, Tetrahedron, 1989, 45(21), 6601-21; and Evans, E. Anthony. Synthesis of radiolabeled compounds, J.
  • Deuterated starting materials are readily available and are subjected to the synthetic methods described herein to provide for the synthesis of deuterium-containing compounds. Large numbers of deuterium-containing reagents and building blocks are available commercially from chemical vendors, such as Aldrich Chemical Co.
  • Deuterium-transfer reagents suitable for use in nucleophilic substitution reactions such as iodomethane-d 3 (CD 3 I) are readily available and may be employed to transfer a deuterium- substituted carbon atom under nucleophilic substitution reaction conditions to the reaction substrate. The use of CD3I is illustrated, by way of example only, in the reaction schemes below.
  • Deuterium-transfer reagents such as lithium aluminum deuteride (LiAlD4)
  • LiAlD4 lithium aluminum deuteride
  • Deuterium gas and palladium catalyst are employed to reduce unsaturated carbon-carbon linkages and to perform a reductive substitution of aryl carbon-halogen bonds as illustrated, by way of example only, in the reaction schemes below.
  • WSGR Docket No.62619-716.601 In one embodiment, the compounds disclosed herein contain one deuterium atom. In another embodiment, the compounds disclosed herein contain two deuterium atoms.
  • the compounds disclosed herein contain three deuterium atoms. In another embodiment, the compounds disclosed herein contain four deuterium atoms. In another embodiment, the compounds disclosed herein contain five deuterium atoms. In another embodiment, the compounds disclosed herein contain six deuterium atoms. In another embodiment, the compounds disclosed herein contain more than six deuterium atoms. In another embodiment, the compound disclosed herein is fully substituted with deuterium atoms and contains no non-exchangeable 1 H hydrogen atoms. In one embodiment, the level of deuterium incorporation is determined by synthetic methods in which a deuterated synthetic building block is used as a starting material. [0061] "Pharmaceutically acceptable salt” includes both acid and base addition salts.
  • a pharmaceutically acceptable salt of any one of the AKT1 inhibitory compounds described herein is intended to encompass any and all pharmaceutically suitable salt forms.
  • Preferred pharmaceutically acceptable salts of the compounds described herein are pharmaceutically acceptable acid addition salts and pharmaceutically acceptable base addition salts.
  • “Pharmaceutically acceptable acid addition salt” refers to those salts which retain the biological effectiveness and properties of the free bases, which are not biologically or otherwise undesirable, and which are formed with inorganic acids such as hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid, phosphoric acid, hydroiodic acid, hydrofluoric acid, phosphorous acid, and the like.
  • salts that are formed with organic acids such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxy alkanoic acids, alkanedioic acids, aromatic acids, aliphatic and. aromatic sulfonic acids, etc.
  • acetic acid trifluoroacetic acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic acid, malonic acid, succinic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid, salicylic acid, and the like.
  • Exemplary salts thus include sulfates, pyrosulfates, bisulfates, sulfites, bisulfites, nitrates, phosphates, monohydrogenphosphates, dihydrogenphosphates, metaphosphates, pyrophosphates, chlorides, bromides, iodides, acetates, trifluoroacetates, propionates, caprylates, isobutyrates, oxalates, malonates, succinate suberates, sebacates, fumarates, maleates, mandelates, WSGR Docket No.62619-716.601 benzoates, chlorobenzoates, methylbenzoates, dinitrobenzoates, phthalates, benzenesulfonates, toluenesulfonates, phenylacetates, citrates, lactates, malates, tartrates, methanesulfonates, and the like.
  • salts of amino acids such as arginates, gluconates, and galacturonates
  • Acid addition salts of basic compounds are, in some embodiments, prepared by contacting the free base forms with a sufficient amount of the desired acid to produce the salt according to methods and techniques with which a skilled artisan is familiar.
  • “Pharmaceutically acceptable base addition salt” refers to those salts that retain the biological effectiveness and properties of the free acids, which are not biologically or otherwise undesirable. These salts are prepared from addition of an inorganic base or an organic base to the free acid.
  • Pharmaceutically acceptable base addition salts are, in some embodiments, formed with metals or amines, such as alkali and alkaline earth metals or organic amines.
  • Salts derived from inorganic bases include, but are not limited to, sodium, potassium, lithium, ammonium, calcium, magnesium, iron, zinc, copper, manganese, aluminum salts and the like.
  • Salts derived from organic bases include, but are not limited to, salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines and basic ion exchange resins, for example, isopropylamine, trimethylamine, diethylamine, triethylamine, tripropylamine, ethanolamine, diethanolamine, 2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine, lysine, arginine, histidine, caffeine, procaine, N,N- dibenzylethylenediamine, chloroprocaine, hydrabamine, choline, betaine, ethylenediamine, ethylenedianiline, N-methylglucamine, glucosamine, methylglucamine, theobromine, purines, piperazine, piperidine, N-ethylpiperidine, polyamine resins and the like.
  • solvates refers to a composition of matter that is the solvent addition form.
  • solvates contain either stoichiometric or non- stoichiometric amounts of a solvent, and are formed during the process of making with pharmaceutically acceptable solvents such as water, ethanol, and the like. Hydrates are formed when the solvent is water, or alcoholates are formed when the solvent is alcohol. Solvates of compounds described herein are conveniently prepared or formed during the processes described herein. The compounds provided herein exist in either unsolvated or solvated forms.
  • the term “subject” or “patient” encompasses mammals.
  • mammals include, but are not limited to, any member of the mammalian class: humans, non-human primates such as chimpanzees, and other apes and monkey species; farm animals such as cattle, horses, sheep, goats, swine; domestic animals such as rabbits, dogs, and cats; laboratory animals including rodents, such as rats, mice and guinea pigs, and the like.
  • the mammal is a human.
  • WSGR Docket No.62619-716.601 As used herein, “treatment” or “treating,” or “palliating” or “ameliorating” are used interchangeably.
  • compositions are, in some embodiments, administered to a patient at risk of developing a particular disease, or to a patient reporting one or more of the physiological symptoms of a disease, even though a diagnosis of this disease has not been made.
  • AKT1 Protein and Function [0067] AKT, also known as protein kinase B (PKB), is a serine/threonine protein kinase with three isoforms, AKT1, AKT2, and AKT3. While the isoforms are encoded by different genes, they are highly homologous at the protein level and share a conserved domain structure comprising an N-terminal pleckstrin homology (PH) domain, a kinase domain, and a C-terminal regulatory domain comprising a hydrophobic moiety, which includes the regulatory serine residue (Nitulescu, G. M. et al., Int J Oncol., 2018; 53(6): 2319-2331).
  • PH N-terminal pleckstrin homology
  • AKT proteins play a crucial role in major cellular functions including cell cycle progression, cell size, regulation of glucose metabolism, transcription, protein synthesis, genome stability, and neovascularization. AKT proteins can block apoptosis by inactivation of pro- apoptotic proteins, and mediate cellular growth factors, promoting cell survival. AKT is a major nucleus of a cell. [0069] AKT1 is ubiquitously expressed, whereas AKT2 is primarily expressed in insulin- responsive tissues, and AKT3 is primarily expressed in brain and testes.
  • a shared phosphorylation site of AKT in the catalytic domain corresponds to a threonine residue; specifically, Thr308 in AKT1, Thr309 in AKT2, and Thr305 in AKT3.
  • a shared phosphorylation site in the C-terminus of the protein c is a serine residue; specifically, Ser473 in AKT1, Ser474 in AKT2, and Ser472 in AKT3.
  • PI3K phosphoinositide-3-kinase
  • AKT cascade can be activated by RTKs and G-protein-compound receptors (GPCRs), along with other signals including integrins, B cell receptors, T cell receptors, and cytokine receptors.
  • GPCRs G-protein-compound receptors
  • AKT1 Mechanism AKT is activated by a second phosphorylation at the regulatory serine residue, Ser473.
  • Known phosphorylating agents of AKT at Ser473 include, but are not limited to PDK-1, integrin-linked kinase (ILK), members of the PI3K-related kinase (PIKK) family, and mammalian target of rapamycin (mTOR) (Nitulescu, G. M.
  • mTOR is a key component in the AKT signaling pathway, which is a downstream member of AKT and an important regulator for cell metabolism and growth. mTOR is also an activator which can directly phosphorylate AKT’s regulatory serine residue, Ser473. mTOR forms a complex with rapamycin-insensitive companion of mTOR (RICTOR) (and other proteins) to form mTOR complex 2 (mTORC2), which can directly phosphorylate AKT Ser473.
  • RICTOR rapamycin-insensitive companion of mTOR
  • mTORC2 mTOR complex 2
  • AKT can affect cell survival and growth because it can influence the tuberous sclerosis complex (TSC) 1/2 along the mTORC signaling pathway and inhibit pro-apoptotic proteins or signals.
  • AKT is known as a survival kinase and mediates cell survival and proliferation by inhibiting pathways including, but not limited to Bcl2 and MDM2, which promotes apoptosis.
  • Bcl2 and MDM2 promotes apoptosis.
  • Malfunctions of AKT typically lead to enhanced proliferation, growth, survival, and resistance to apoptosis (Alwhaibi, A. et al., Pharmacol Res., 2019, 145: 104270).
  • AKT1 has been found to be involved in invasion and migration of cancerous cells (Alwhaibi, A. et al., Pharmacol Res., 2019, 145: 104270). researchers found that silencing the AKT1 isoform can abrogate specific types of cancer cell migration. However, there have been other studies which have demonstrated that activated AKT1 resulted in less metastatic propensity for lung metastatic lesion cells and breast cancer cells.
  • AKT1 has also been identified as a key protein involved in angiogenesis, lung cancer, and tumorigenesis.
  • overexpression of AKT has been correlated to resistance to chemotherapeutic agents such as cisplatin, methotrexate, and paclitaxel.
  • chemotherapeutic agents such as cisplatin, methotrexate, and paclitaxel.
  • chemotherapeutic agents such as cisplatin, methotrexate, and paclitaxel.
  • WSGR Docket No.62619-716.601 Recently, it has been found that the AKT1 gene mutation E17K can affect cell growth, proliferation, survival, and migration of breast cancer cells, colorectal cancer cells, and ovarian cancer cells (Chen, Y. et al., Front Cell Dev Biol., 2020; 8: 573599).
  • AKT1 to Phosphatidylinositol-3,4,5-triphosphate (PIP3) lipid ligand, which accelerates transfer of AKT from the cytoplasm to the cell membrane through formation of hydrogen bonds. Transfer of AKT into the cell membrane allows it to be further phosphorylated. Once fully activated, AKT can return to the cytoplasm, or go to the nucleus or other intracellular sites, and phosphorylate other substrate proteins to regulate cell function.
  • PIP3 Phosphatidylinositol-3,4,5-triphosphate
  • a major pathway that activates PI3K-AKT signaling pathway is somatic cell mutations, with the E17K mutation being the highest frequency of AKT1 mutations. It is nearly exclusively present in AKT1.
  • the AKT1(E17K) is a recurrent somatic cell mutation predominantly in breast cancer, ovarian cancer, meningioma, and Proteus syndrome.
  • AKT1(E17K) mutations mediate the PI3K-AKT signaling cascade by expanding PIP lipid specificity, which causes conformational changes. This also enhances subcellular localization to accelerate localization of the PH structural domain to the plasma membrane.
  • the E17K mutation increases PIP3 binding specificity by 7-fold and phosphatidylinositol-(4,5)- bisphosphate (PIP2) by 100-fold.
  • PIP2 phosphatidylinositol-(4,5)- bisphosphate
  • the AKT1(E17K) mutation also causes rapid conformational changes in the AKT1 PH structural domain. The conformational changes to this domain result in a 4.5-fold increase in its membrane localization, which can result in excessive phosphorylation.
  • the AKT1(E17K) mutation can also result in enhanced subcellular localization by increasing the transient expression. [0082] Given the conformational and signaling effects of the AKT1(E17K) mutation, this target may be useful for targeted treatment of cancers.
  • Prior Art AKT1 Inhibitors [0083] Most AKT inhibitors targeting the ATP binding site are non-selective against the three isoforms, as well as having poor to no selectivity against other structurally similar kinases. Thus, there remains a need to develop new and novel AKT inhibitors.
  • ATP targeting inhibitors are classified as aminofurazans, azepane derivatives, isoquinoline-5-sulfonamides, WSGR Docket No.62619-716.601 phenylpyrazole derivatives, thiophene carboxamide derivatives, and thiazole carboxamide derivatives.
  • ATP non-competitive AKT inhibitors which are allosteric modulators which have greater specificity than the ATP targeting inhibitors.
  • Many of these allosteric modulator inhibitors are classified as purine derivatives, thiourea derivatives, alkylphospholipids, sulfonamides, 2,3-diphenylquinoxaline analogs, and indole-3-carbinol derivatives.
  • an AKT1 inhibitory compound In one aspect, provided herein is an AKT1 inhibitory compound.
  • One embodiment provides a compound having the structure of Formula (I), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; X is -C(O)-, or -S(O) 2 -; R 1 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 2 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, optionally substituted heterocyclyl, optionally substituted C3-C10 carbocyclyl, or optionally substituted heteroaryl; R 3 is selected from halogen, -CN, optionally substituted C1-C6 al
  • One embodiment provides a compound having the structure of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof: wherein: Z 1 is N, C-H, or C-R 3 ; Z 2 is N, C-H, or C-R 4 ; R 1 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; WSGR Docket No.62619-716.601 R 2 is selected from hydrogen, halogen, -CN, optionally substituted C1-C6 alkyl, optionally substituted aryl, or optionally substituted heteroaryl; R 3 is selected from halogen, -CN, optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 4 is selected from halogen, -CN, optionally substituted C1-C6 alkyl, or optionally substituted aryl; R 5 and R 6 are each independently hydrogen, deuterium
  • One embodiment provides an AKT1 inhibitory compound, or a pharmaceutically acceptable salt or solvate thereof, having a structure presented in Table 1.
  • Table 1 WSGR Docket No.62619-716.601
  • WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601
  • WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601
  • WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601
  • WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601
  • WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601
  • WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601
  • “Commercially available chemicals” are obtained from standard commercial sources including Acros Organics (Pittsburgh, PA), Aldrich Chemical (Milwaukee, WI, including Sigma Chemical and Fluka), Apin Chemicals Ltd. (Milton Park, UK), Avocado Research (Lancashire, U.K.), BDH Inc. (Toronto, Canada), Bionet (Cornwall, U.K.), Chemservice Inc. (West Chester, PA), Crescent Chemical Co. (Hauppauge, NY), Eastman Organic Chemicals, Eastman Kodak Company (Rochester, NY), Fisher Scientific Co. (Pittsburgh, PA), Fisons Chemicals (Leicestershire, UK), Frontier Scientific (Logan, UT), ICN Biomedicals, Inc.
  • compositions WSGR Docket No.62619-716.601 In certain embodiments, the AKT1 inhibitory compound described herein is administered as a pure chemical. In other embodiments, the AKT1 inhibitory compound described herein is combined with a pharmaceutically suitable or acceptable carrier (also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier) selected on the basis of a chosen route of administration and standard pharmaceutical practice as described, for example, in Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
  • a pharmaceutically suitable or acceptable carrier also referred to herein as a pharmaceutically suitable (or acceptable) excipient, physiologically suitable (or acceptable) excipient, or physiologically suitable (or acceptable) carrier
  • a pharmaceutical composition comprising at least one AKT1 inhibitory compound as described herein, or a stereoisomer, pharmaceutically acceptable salt, hydrate, or solvate thereof, together with one or more pharmaceutically acceptable carriers.
  • the carrier(s) or excipient(s)
  • One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof.
  • One embodiment provides a method of preparing a pharmaceutical composition comprising mixing a compound of Formula (I), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof.
  • One embodiment provides a method of preparing a pharmaceutical composition comprising mixing a compound of Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • the AKT1 inhibitory compound as described by Formula (I), or a pharmaceutically acceptable salt or solvate thereof is substantially pure, in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
  • the AKT1 inhibitory compound as described by Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof is substantially pure, in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less WSGR Docket No.62619-716.601 than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
  • One embodiment provides a pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof.
  • One embodiment provides a method of preparing a pharmaceutical composition
  • a method of preparing a pharmaceutical composition comprising mixing a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable carrier.
  • the AKT1 inhibitory compound as described by Table 1, or a pharmaceutically acceptable salt or solvate thereof is substantially pure, in that it contains less than about 5%, or less than about 2%, or less than about 1%, or less than about 0.5%, or less than about 0.1%, of other organic small molecules, such as unreacted intermediates or synthesis by-products that are created, for example, in one or more of the steps of a synthesis method.
  • Suitable oral dosage forms include, for example, tablets, pills, sachets, or capsules of hard or soft gelatin, methylcellulose or of another suitable material easily dissolved in the digestive tract.
  • suitable nontoxic solid carriers include, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharin, talcum, cellulose, glucose, sucrose, magnesium carbonate, and the like. (See, e.g., Remington: The Science and Practice of Pharmacy (Gennaro, 21 st Ed. Mack Pub. Co., Easton, PA (2005)).
  • the AKT1 inhibitory compound as described by Formula (I) or Formula (Ia) or Table 1, or pharmaceutically acceptable salt or solvate thereof is formulated for administration by injection.
  • the injection formulation is an aqueous formulation.
  • the injection formulation is a non-aqueous formulation.
  • the injection formulation is an oil-based formulation, such as sesame oil, or the like.
  • the dose of the composition comprising at least one AKT1 inhibitory compound as described herein differs depending upon the subject or patient's (e.g., human) condition. In some embodiments, such factors include general health status, age, and other factors.
  • compositions are administered in a manner appropriate to the disease to be treated (or prevented).
  • An appropriate dose and a suitable duration and frequency of administration will be determined by such factors as the condition of the patient, the type and severity of the patient's disease, the particular form of the active ingredient, and the method of administration.
  • an appropriate dose and treatment regimen provides the composition(s) in an amount sufficient to provide therapeutic and/or prophylactic benefit (e.g., an improved clinical outcome, such as more frequent complete or partial remissions, or longer WSGR Docket No.62619-716.601 disease-free and/or overall survival, or a lessening of symptom severity.
  • Optimal doses are generally determined using experimental models and/or clinical trials.
  • One embodiment provides a compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.
  • One embodiment provides a compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of cancer or neoplastic disease.
  • One embodiment provides a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient for use in a method of treatment of cancer or neoplastic disease.
  • One embodiment provides a use of a compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.
  • a method of treating cancer in a patient in need thereof, comprising administering to the patient a compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof.
  • a method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprising a compound of Formula (I) or Formula (Ia), or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
  • One embodiment provides a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of the human or animal body.
  • One embodiment provides a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, for use in a method of treatment of cancer or neoplastic disease.
  • One embodiment provides a pharmaceutical composition comprising a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient for use in a method of treatment of cancer or neoplastic disease.
  • One embodiment provides a use of a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, in the manufacture of a medicament for the treatment of cancer or neoplastic disease.
  • WSGR Docket No.62619-716.601 In some embodiments is provided a method of treating cancer, in a patient in need thereof, comprising administering to the patient a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof.
  • a method of treating cancer in a patient in need thereof, comprising administering to the patient a pharmaceutical composition comprising a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
  • a pharmaceutical composition comprising a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable excipient.
  • the pharmaceutical composition is administered orally.
  • the pharmaceutical composition is administered by injection.
  • One embodiment provides a method of inhibiting an AKT1 enzyme comprising contacting the AKT1 enzyme with a compound of Formula (I) or Formula (Ia), or Table 1.
  • Another embodiment provides the method of inhibiting an AKT1 enzyme, wherein the AKT1 enzyme is contacted in an in vivo setting.
  • Another embodiment provides the method of inhibiting an AKT1 enzyme, wherein the AKT1 enzyme is contacted in an in vitro setting.
  • AKT1 enzyme is contacted in an in vitro setting.
  • Other embodiments and uses will be apparent to one skilled in the art in light of the present disclosures. The following examples are provided merely as illustrative of various embodiments and shall not be construed to limit the invention in any way.
  • Step 2 tert-Butyl N-[[4-[2-(2-amino-3-pyridyl)-5-chloro-imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]carbamate
  • tert-butyl N-[[4-[(6-chloro-3-nitro-2- pyridyl)amino]phenyl]methyl]carbamate 2.0 g, 5.3 mmol
  • 2-aminopyridine-3-carbaldehyde 0.7 g, 5.8 mmol
  • Na 2 S 2 O 4 1.8 g, 10.6 mmol
  • Step 3 tert-Butyl N-[[4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]carbamate
  • tert-butyl N-[[4-[2-(2-amino-3-pyridyl)-5-chloro-imidazo[4,5- b]pyridin-3-yl]phenyl]methyl]carbamate 500 mg, 1.1 mmol
  • phenylboronic acid 270 mg, 2.2 mmol,
  • 1,4-dioxane 5 mL
  • H2O 1,4-dioxane
  • Pd(dppf)Cl2 81.1 mg, 111 ⁇ mol
  • Cs 2 CO 3 1.1 g, 3.3 mmol
  • the mixture was degassed and purged with N 2 three times and then stirred at 80 °C for 16 hr under N2 atmosphere. After cooling to 20 °C, the reaction was diluted with EtOAc (10 mL), filtered through celite, and extracted with H2O (10 mL x 3). The combined organic layers were washed with brine (15 mL x 3), dried over Na 2 SO 4, filtered and concentrated under reduced pressure.
  • Step 4 3-(3-(4-(Aminomethyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
  • the crude product was purified by prep-HPLC (column: Welch Xtimate C18 150 * 25mm, 5 ⁇ m; mobile phase: [water (HCl) - ACN]; B%: 5% - 35%, 8min) to give the desired product (HCl salt).
  • the product was diluted with aqueous NaHCO 3 (10 mL) and extracted with DCM (10 mL x 3).
  • Step 2 tert-Butyl 4-[[4-[(3-nitro-6-phenyl-2-pyridyl)amino]phenyl]methyl]piperazine- 1-carboxylate [00135] To a solution of tert-butyl 4-[[4-[(6-chloro-3-nitro-2- pyridyl)amino]phenyl]methyl]piperazine-1-carboxylate (1.0 g, 2.23 mmol) and phenylboronic acid (544 mg, 4.47 mmol) in 1,4-dioxane (10 mL) and H 2 O (2 mL) were added Pd(dppf)Cl 2 (327 mg, 0.446 mmol) and K2CO3 (926 mg, 6.7 mmol).
  • Step 3 tert-Butyl 4-[[4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methyl]piperazine-1-carboxylate [00137] To a solution of 2-aminopyridine-3-carbaldehyde (269 mg, 2.21 mmol) and tert-butyl 4-[[4-[(3-nitro-6-phenyl-2-pyridyl)amino]phenyl]methyl]piperazine-1-carboxylate (900 mg, 1.84 mmol) in DMSO (10 mL) was added Na2S2O4 (960 mg, 5.52 mmol) at 15 °C.
  • the mixture was stirred at 100 °C for 20 hr.
  • the reaction mixture was diluted with H 2 O (50 mL) and extracted with DCM (80 mL x 3). The combined organic layers were washed with brine (80 mL x 3), dried over Na2SO4, filtered, and concentrated under reduced pressure.
  • Step 4 3-(5-Phenyl-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
  • Step 1 tert-Butyl (1-(4-((6-chloro-3-nitropyridin-2-yl)amino)benzyl)piperidin-4- yl)carbamate [00141] To a solution of 2,6-dichloro-3-nitro-pyridine (3.0 g, 15.5 mmol) and tert-butyl N-[1- [(4-aminophenyl)methyl]-4-piperidyl]carbamate (4.8 g, 15.6 mmol) in 1,4-dioxane (100 mL) was added DIEA (6.0 g, 46.6 mmol).
  • Step 2 tert-Butyl N-[1-[[4-[(3-nitro-6-phenyl-2-pyridyl)amino]phenyl]methyl]-4- piperidyl]carbamate
  • a mixture of tert-butyl N-[1-[[4-[(6-chloro-3-nitro-2-pyridyl)amino]phenyl]methyl]-4- piperidyl]carbamate 1.0 g, 2.20 mmol
  • phenylboronic acid (528 mg, 4.30 mmol)
  • Pd(dppf)Cl2 158 mg, 0.216 mmol
  • K 2 CO 3 898 mg, 6.50 mmol
  • 1,4-dioxane (10 mL) and H 2 O (2 mL) was degassed and purged with N 2 three times, and then the mixture was stirred at 100 °C for 12 hr under N2 atmosphere.
  • Step 3 tert-Butyl (1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl) carbamate
  • 2-aminopyridine- 3-carbaldehyde 53.4 mg, 0.437 mmol
  • Na2S2O4 207 mg, 1.2 mmol
  • Step 4 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-5-phenyl-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine [00147] To a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)carbamate (200 mg, 0.347 mmol) in HCl in 1,4-dioxane (4 M, 2 mL). The mixture was stirred at 25 °C for 2 hr.
  • Step 1 Methyl 4-((6-chloro-3-nitropyridin-2-yl)amino)benzoate [00150] To a solution of methyl 4-aminobenzoate (5 g, 33.1 mmol) in DMSO (50 mL) were added 2,6-dichloro-3-nitro-pyridine (7.66 g, 39.7 mmol) and DIEA (12.82 g, 99.2 mmol).
  • Step 2 Methyl 4-((3-nitro-6-phenylpyridin-2-yl)amino)benzoate
  • methyl 4-[(6-chloro-3-nitro-2-pyridyl)amino]benzoate (45 g, 146 mmol) and phenylboronic acid (21.4 g, 176 mmol) in 1,4-dioxane (500 mL) and H 2 O (100 mL) were added Pd(dppf)Cl 2 (10.7 g, 14.6 mmol) and Cs 2 CO 3 (143 g, 439 mmol).
  • Step 3 Methyl 4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzoate WSGR Docket No.62619-716.601
  • 2-aminopyridine-3-carbaldehyde 6.29 g, 51.5 mmol
  • Na 2 S 2 O 4 15 g, 85.9 mmol
  • Step 4 (4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
  • LiAlH4 450 mg, 11.9 mmol
  • the reaction mixture was stirred at 25 °C for 2 hr.
  • the reaction mixture was quenched with H 2 O (100 mL), followed with15% aqueous NaOH (30 mL). Then the reaction mixture was filtered.
  • Step 5 3-(3-(4-(Chloromethyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine [00158] To a solution of [4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5-b]pyridin-3- yl]phenyl]methanol (2.3 g, 5.9 mmol) in CH2Cl2 (25 mL) was added SOCl2 (2.1 g, 17.5 mmol). The mixture was stirred at 40°C for 1 hr. The reaction mixture was filtered.
  • Step 2 3-(3-(4-((2,6-Diazaspiro[3.3]heptan-2-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00163] To a solution of tert-butyl 6-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,6-diazaspiro[3.3]heptane-2-carboxylate (Intermediate 5, 150 mg, 261 ⁇ mol) in CH 2 Cl 2 (3 mL) was added TFA (1.54 g, 13.5 mmol) at 25 °C.
  • Step 1 tert-Butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-1,4-diazepane-1-carboxylate [00178] To a solution of Intermediate 4 (1 g, 2.43 mmol), tert-butyl 1,4-diazepane-1- carboxylate (584 mg, 2.92 mmol) in ACN (20 mL) were added NaI (36.4 mg, 243 ⁇ mol) and K 2 CO 3 (671 mg, 4.86 mmol).
  • Step 2 3-(3-(4-((1,4-Diazepan-1-yl)methyl)phenyl)-5-phenyl-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine [00180] To a solution of tert-butyl 4-[[4-[2-(2-amino-3-pyridyl)-5-phenyl-imidazo[4,5- b]pyridin-3-yl]phenyl]methyl]-1,4-diazepane-1-carboxylate (520 mg, 0.903 mmol) in HCl/1,4- dioxane (4M, 10 mL). The mixture was stirred at 25 C for 1 hr.
  • Step 2 (R)-3-(3-(4-((2,7-Diazaspiro[4.4]nonan-2-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
  • R tert-butyl
  • Step 2 3-(3-(4-(((3R,5R)-3,5-Dimethylpiperazin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
  • Step 2 tert-Butyl 4-(4-aminobenzyl)piperazine-1-carboxylate [00249] To a solution of tert-butyl 4-(4-nitrobenzyl)piperazine-1-carboxylate(20 g, 62.2 mmol) in EtOH (150 mL) and H2O (50 mL) were added Fe (17.3 g, 311 mmol) and NH4Cl (13.3 g, 249 mmol) at 25 °C. The mixture was stirred at 90 °C for 2 hr.
  • Step 3 tert-Butyl 4-(4-((3-nitropyridin-2-yl)amino)benzyl)piperazine-1-carboxylate
  • 2-chloro-3-nitro-pyridine 10 g, 63 mmol
  • DMSO 200 mL
  • tert-butyl 4-(4-aminobenzyl)piperazine-1-carboxylate 15.3 g, 52.5 mmol
  • DIEA (13.5 g, 105 mmol
  • Step 4 tert-Butyl 4-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazine-1-carboxylate
  • 2-aminopyridine-3-carbaldehyde 3.54 g, 29.0 mmol
  • Na 2 S 2 O 4 (12.6 g, 72.5 mmol) at 25 °C.
  • Step 5 3-(3-(4-(Piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin- 2-amine
  • tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazine-1-carboxylate (2 g, 4.12 mmol) in CH2Cl2 (10 mL) was added dropwise TFA (4.62 g, 40.5 mmol) at 25 °C, and the mixture was stirred at 25 °C for 3 hr. The reaction mixture was concentrated.
  • Step 1 tert-Butyl (1-(4-nitrobenzyl) piperidin-4-yl) carbamate [00258] To a solution of 1-(bromomethyl)-4-nitro-benzene (108 g, 499 mmol) in ACN (1.5 L) were added K 2 CO 3 (149 g, 1.1 mol) and tert-butyl N-(4-piperidyl)carbamate (100 g, 499 mmol).
  • Step 2 tert-Butyl (1-(4-aminobenzyl) piperidin-4-yl) carbamate
  • tert-butyl (1-(4-nitrobenzyl) piperidin-4-yl)carbamate 109 g, 325 mmol
  • EtOH 500 mL
  • H 2 O 150 mL
  • Fe 91 g, 1.6 mol
  • NH 4 Cl 174 g, 3.3 mol
  • Step 3 tert-Butyl (1-(4-((3-nitropyridin-2-yl) amino)benzyl)piperidin-4-yl)carbamate WSGR Docket No.62619-716.601
  • tert-butyl (1-(4-aminobenzyl) piperidin-4-yl) carbamate (30 g, 98.2 mmol) in DMSO (500 mL) were added DIEA (38.1 g, 295 mmol) and 2-chloro-3-nitro-pyridine (18.7 g, 118 mmol). The mixture was stirred at 100 °C for 16 hr.
  • Step 4 tert-Butyl (1-(4-(2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)carbamate
  • Na2S2O4 (15.3 g, 87.7 mmol
  • 2-aminopyridine-3-carbaldehyde 4.3 g, 35.1 mmol
  • the mixture was stirred at 100 °C for 16 hr.
  • the reaction mixture was quenched with H2O (300 WSGR Docket No.62619-716.601 mL) at 25°C and extracted with CH2Cl2 (500 mL x 2).
  • the combined organic layers were washed with H 2 O (1000 mL x 3), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 2 3-(5-Cyclopropyl-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine
  • HCl/1,4-dioxane 4 M, 1 mL
  • Step 2 tert-Butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazine-1-carboxylate
  • 2-aminonicotinaldehyde 9 mg, 994 ⁇ mol
  • Na2S2O4 542 mg, 2.65 mmol
  • Step 3 3-(5-Morpholino-3-(4-(piperazin-1-ylmethyl)phenyl)-3H-imidazo[4,5-b]pyridin- 2-yl)pyridin-2-amine
  • tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate 270 mg, 473 ⁇ mol
  • the mixture was stirred at 100 °C for 16 hr under N2 atmosphere.
  • the reaction mixture was filtered at 25°C, diluted with H 2 O (20 mL), and extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
  • Step 2 3-(2-(2-Aminopyridin-3-yl)-3-(4-(piperazin-1-ylmethyl)phenyl)-3H- imidazo[4,5-b]pyridin-5-yl)benzonitrile [00291] To a solution of tert-butyl 4-(4-(2-(2-aminopyridin-3-yl)-5-(3-cyanophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazine-1-carboxylate (240 mg, 409 ⁇ mol) in 1,4-dioxane for 16 hr. The reaction mixture was filtered.
  • Step 2 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-5-cyclopropyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
  • a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5- 3 mL) was stirred at 25 °C for 1 hr.
  • Step 2 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-5-(3,6-dihydro-2H-pyran-4- yl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00317] To a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-(3,6-dihydro-2H-pyran-4- yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)carbamate CH2Cl2 (4 mL) was added HCl in 1,4-dioxane (4 M, 4 mL).
  • the mixture was stirred at 25 °C for 0.5 hr.
  • the reaction mixture was concentrated under reduced pressure.
  • the residue was diluted with H2O (100 mL) and washed with EtOAc (150 mL).
  • the pH of the aqueous phase was adjusted to 8 with saturated NaHCO3.
  • the aqueous was extracted with EtOAc (50 mL x 3).
  • the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 2 tert-Butyl (1-(4-((3-nitro-5-phenylpyridin-2-yl)amino)benzyl)piperidin-4- yl)carbamate
  • Step 3 tert-Butyl (1-(4-(2-(2-aminopyridin-3-yl)-6-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)carbamate
  • 2-aminopyridine-3-carbaldehyde (694 mg, 5.7 mmol)
  • Na2S2O4 1.5 g, 8.7 mmol
  • DMSO 100 mL
  • Step 4 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-6-phenyl-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine WSGR Docket No.62619-716.601
  • Step 2 Benzyl 4-((tert-butoxycarbonyl)(methyl-d3)amino)piperidine-1-carboxylate
  • benzyl 4-(tert-butoxycarbonylamino)piperidine-1-carboxylate 13 g, 38.9 mmol
  • NaH 4.66 g, 117 mmol
  • CD3I 16.5 g, 117 mmol
  • Step 3 tert-Butyl (methyl-d3)(piperidin-4-yl)carbamate
  • benzyl 4-[tert-butoxycarbonyl(trideuteriomethyl)amino]piperidine-1- carboxylate 8.6 g, 24.5 mmol
  • MeOH 90 mL
  • Pd/C 900 mg, 24.5 mmol
  • the WSGR Docket No.62619-716.601 mixture was stirred at 25 °C for 16 hr under H2 (15 psi). The mixture was filtered, and the filter cake was washed with MeOH (30 mL).
  • Step 4 tert-Butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)(methyl-d3)carbamate
  • tert-butyl (methyl-d3)(piperidin-4-yl)carbamate 527 mg, 2.43 mmol
  • NaI 182 mg, 1.21 mmol
  • K2CO3 1.0 g, 7.28 mmol
  • reaction mixture was diluted with H 2 O (20 mL) and extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed with brine (20 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure. The residue was purified by silica gel flash chromatography (Eluent of 0 ⁇ 6% MeOH in CH 2 Cl 2 ) to give tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)(methyl-d3)carbamate (750 mg, yield: 49%) as a yellow solid.
  • Step 5 3-(3-(4-((4-((Methyl-d 3 )amino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00353] To a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)(methyl-d3)carbamate (430 mg, 725 ⁇ mol) in CH 2 Cl 2 (5 mL) was added TFA (165 mg, 1.45 mmol).
  • the mixture was stirred at 25 °C for 1 hr.
  • the mixture was diluted with H2O (10 mL).
  • the pH of the mixture was adjusted to about 8 with NaHCO 3 (aq.).
  • the mixture was extracted with CH 2 Cl 2 (10 mL x 2).
  • the combined organic layers were washed with brine (10 mL x 2), dried over Na2SO4, filtered, and concentrated under reduced pressure.
  • Step 2 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3-yl)-3H- imidazo[4,5-b]pyridin-5-yl)benzonitrile
  • tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-(3-cyanophenyl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)carbamate (50 mg, 73 ⁇ mol) in 1,4-dioxane (2 mL) was added 4M HCl in 1,4-dioxane (2 mL).
  • Step 2 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-5-cyclohexyl-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine WSGR Docket No.62619-716.601 [00365] To a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-cyclohexyl-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)carbamate (182 mg, 345 ⁇ mol) in 1,4-dioxane (2 mL) was added 4 M HCl in 1,4-dioxane (2.0 mL).
  • Step 1 tert-Butyl 4-(N-methylacrylamido)piperidine-1-carboxylate [00368] To a mixture of tert-butyl 4-(methylamino)piperidine-1-carboxylate (5 g, 23.3 mmol) and DIEA (9.05 g, 69.9 mmol) in THF (200 mL) was added acryloyl chloride (2.11 g, 23.3 mmol) dropwise at 0 °C. The mixture was stirred at 0 °C for 1 hr.
  • Step 2 (N-methyl-N-(piperidin-4-yl)acrylamide
  • TFA N-methyl-N-(piperidin-4-yl)acrylamide
  • Step 1 (4-((3-Nitropyridin-2-yl)amino)phenyl)methanol [00373] To a solution of (4-aminophenyl)methanol (10 g, 81.2 mmol) in 1,4-dioxane (150 mL) were added DIEA (31.5 g, 244 mmol) and 2-chloro-3-nitro-pyridine (15.5 g, 97.4 mmol).
  • Step 2 (4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3-yl)phenyl)methanol
  • 4-((3-nitropyridin-2-yl)amino)phenyl)methanol 10 g, 40.8mmol
  • DMSO 500 mL
  • Na 2 S 2 O 4 21.3 g, 122 mmol
  • 2-aminopyridine-3-carbaldehyde 5.98 g, 48.9 mmol
  • Step 3 3-(3-(4-(Chloromethyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00377] To a solution of (4-(2-(2-aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol (1.0 g, 3.15 mmol) in CH 2 Cl 2 (10 mL) was added SOCl 2 (3.3 g, 27.6 mmol). The mixture was stirred at 40 °C for 1 hr.
  • Step 2 4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-amine hydrochloride
  • tert-butyl(4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)carbamate 800 mg, 1.39 mmol
  • 1,4-dioxane (10 mL) WSGR Docket No.62619-716.601
  • the mixture was filtered and concentrated to give 4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazin-1-amine hydrochloride (Intermediate
  • Step 2 Benzyl 4-((tert-butoxycarbonyl)(methyl)amino)piperazine-1-carboxylate
  • benzyl 4-((tert-butoxycarbonyl)amino)piperazine-1-carboxylate 1.2 g, 3.58 mmol
  • THF 10 mL
  • NaH 429 mg, 60% purity
  • CH3I 1.02 g, 7.16 mmol
  • Step 3 tert-Butyl methyl(piperazin-1-yl)carbamate
  • benzyl 4-((tert-butoxycarbonyl)(methyl)amino)piperazine-1- carboxylate 1.1 g, 3.15 mmol
  • MeOH MeOH
  • Pd/C 1.1 g, 10% purity
  • the mixture was stirred at 25 °C for 12 hr under H 2 (50 psi).
  • the mixture was filtered and concentrated to give tert-butyl methyl(piperazin-1-yl)carbamate (670 mg, yield: 99%) as an off- white solid, which was used into the next step without purification.
  • Step 5 4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-N-methylpiperazin-1-amine [00395] To a solution of tert-butyl (4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b N 2 .
  • Step 2 Methyl 4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5-b]pyridin-3- yl)benzoate
  • a mixture of methyl 4-((6-morpholino-3-nitropyridin-2-yl)amino)benzoate (2.94 g, 8.20 mmol), 2-aminonicotinaldehyde (1.10 g, 9.02 mmol), and Na 2 S 2 O 4 (5.71 g, 32.8 mmol) in DMSO (30 mL) was stirred at 100 °C for 16 hr. The reaction mixture was cooled to room temperature and the pH was adjusted to about 9 with sat.
  • Step 4 3-(3-(4-(Chloromethyl)phenyl)-5-morpholino-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
  • Step 4 3-(3-(4-(Chloromethyl)phenyl)-5-morpholino-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine
  • Step 5 tert-Butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)(methyl)carbamate
  • 3-(3-(4-(chloromethyl)phenyl)-5-morpholino-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine 600 mg, 1.43 mmol
  • tert-butyl methyl(piperidin-4- K2CO3 985 mg, 7.13 mmol
  • Step 6 3-(3-(4-((4-(Methylamino)piperidin-1-yl)methyl)phenyl)-5-morpholino-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00410] To a mixture of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)(methyl)carbamate CH2Cl2 (5 mL) was added HCl/1,4-dioxane (4 M, 1 mL).
  • Step 2 Methyl 4-(2-(2-aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5-b]pyridin-3- yl)benzoate WSGR Docket No.62619-716.601
  • 2-aminopyridine-3-carbaldehyde 9.4 g, 76.6 mmol
  • Na 2 S 2 O 4 44.5 g, 255 mmol
  • Step 3 (4-(2-(2-Aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
  • Step 3 (4-(2-(2-Aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5-b]pyridin-3- yl)phenyl)methanol
  • Step 4 3-(3-(4-(Chloromethyl)phenyl)-5-cyclopropyl-3H-imidazo[4,5-b]pyridin-2- yl)pyridin-2-amine [00419] To a solution of (4-(2-(2-aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5-b]pyridin- 3-yl)phenyl)methanol (1.4 g, 3.9 mmol) in CH2Cl2 (20 mL) was added SOCl2 (2.8 g, 23.5 mmol) dropwise at 25 °C. The mixture was stirred at 40 °C for 1 hr.
  • Step 2 3-(3-(4-((4-Aminopiperidin-1-yl)methyl)phenyl)-5-morpholino-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine
  • Na 2 S 2 O 4 (3.88 g, 18.9 mmol) in DMSO (90 mL) was stirred at 100 °C for 24 hr.
  • the reaction mixture was diluted with H2O (200 mL) and extracted with CH 2 Cl 2 (50 mL x 3). The pH of the mixture was adjusted to about 8 ⁇ 9 using sat. Na 2 CO 3 (100 mL). The mixture was extracted with EtOAc (50 mL x 6), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Step 2 Benzyl 4-((tert-butoxycarbonyl)(cyclopropyl)amino)piperidine-1-carboxylate
  • benzyl 4-(cyclopropylamino)piperidine-1-carboxylate 580 mg, 2.11 mmol
  • H 2 O 5 mL
  • Na 2 CO 3 672 mg, 6.34 mmol
  • Boc 2 O
  • Step 3 tert-Butyl cyclopropyl(piperidin-4-yl)carbamate
  • benzyl 4-((tert-butoxycarbonyl)(cyclopropyl)amino)piperidine-1- carboxylate 500 mg, 1.34 mmol
  • MeOH MeOH
  • Pd/C 150 mg, 10% purity
  • the mixture was purged with H 2 three times and stirred at 40 °C under H 2 atmosphere (40 Psi) for 16 hr.
  • the mixture was filtered and washed with MeOH (10 mL x 2).
  • Step 4 tert-Butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)(cyclopropyl)carbamate
  • 2 CO 3 tert-butyl cyclopropyl(piperidin-4- yl)carbamate (350 mg, 1.46 mmol). The mixture was stirred at 25 °C for 16 hr. The reaction mixture was quenched with H2O (10 mL) at 25 °C, diluted with EtOAc (15 mL) and washed with H 2 O (20 mL x 3).
  • Step 5 3-(3-(4-((4-(Cyclopropylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00435] To a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b CH2Cl2 (3 the mixture was adjusted to 8 with saturated NaHCO3. The mixture was diluted with CH2Cl2 (15 mL), extracted with CH2Cl2 (20 mL x 3).
  • Step 2 3-(3-(4-((4-(Ethylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00440] To a solution of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)(ethyl)carbamate (320 mg, 530 ⁇ mol) in 1,4-dioxane (3.0 mL) was added 4M HCl in 1,4-dioxane (3.0 mL).
  • Example 1 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)acrylamide
  • DIEA 329 mg, 2.55 mmol
  • HOBt 103 mg, 764 mmol
  • EDCI 147 mg, 764 mmol
  • Example 2 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)prop-2-en-1-one [00446] To a solution of Intermediate 2 (150 mg, 325 mmol) and prop-2-enoyl chloride (58.8 mg, 650 mmol) in THF (3 mL) was added TEA (164 mg, 1.62 mmol). The mixture was stirred at 0 °C for 1 hr.
  • Example 3 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)acrylamide
  • DIEA DIEA
  • Example 4 N-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)ethenesulfonamide
  • TEA 2.9 mg, 127 mmol
  • 2-chloroethanesulfonyl chloride 20.8 mg, 127 mmol
  • Example 5 3-(5-Phenyl-3-(4-((4-(vinylsulfonyl)piperazin-1-yl)methyl)phenyl)-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00452] To a solution of Intermediate 2 (200 mg, 433 ⁇ mol) and ethenesulfonyl chloride (55 mg, 433 ⁇ mol) in CH2Cl2 (5 mL) was added TEA (219 mg, 2.17 mmol). The mixture was stirred at 25 °C for 14 hr. The reaction mixture was filtered and concentrated under reduced pressure.
  • Example 6 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)ethenesulfonamide [00454]
  • Example 7 (E)-1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperazin-1-yl)-3-methoxyprop-2-en-1-one [00456] To a solution of Intermediate 2 (200 mg, 329 mmol) and TEA (66.6 mg, 659 mmol) in CH 2 Cl 2 (4 mL) was added (E)-3-methoxyacrylic acid (43.7 mg, 428 mmol), EDCI (94.7 mg, 494 mmol) and DMAP (4.02 mg, 32.9 mmol).
  • the mixture was stirred at 25 °C for 12 hr.
  • the reaction mixture was diluted with H2O (10 mL) and extracted with CH2Cl2 (10 mL ⁇ 3). The combined organic layers were dried over Na 2 SO 4 , filtered, and concentrated under reduced pressure.
  • Example 8 (E)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)-3-methoxyacrylamide [00458]
  • Example 9 1-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,6-diazaspiro[3.3]heptan-2-yl)prop-2-en-1-one [00460]
  • Example 10 (S)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-3-yl)acrylamide [00462]
  • Example 11 (S)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)pyrrolidin-3-yl)acrylamide [00464]
  • Example 12 N-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2-azaspiro[4.5]decan-8-yl)acrylamide [00466]
  • Example 12 was prepared in a manner similar to Example 2.
  • Example 13 (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-3-yl)acrylamide WSGR Docket No.62619-716.601 [00468]
  • Example 14 (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)pyrrolidin-3-yl)acrylamide [00470]
  • Example 15 N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azetidin-3-yl)acrylamide [00472]
  • Example 16 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-1,4-diazepan-1-yl)prop-2-en-1-one WSGR Docket No.62619-716.601 [00474]
  • Example 17 N-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-7-azaspiro[3.5]nonan-2-yl)acrylamide [00476]
  • Example 18 N-(2-(4-(2-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2-azaspiro[3.3]heptan-6-yl)acrylamide [00478]
  • Example 19 N-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2-azaspiro[3.5]nonan-7-yl)acrylamide [00480]
  • Example 20 N-(2-(4-(2-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2-azaspiro[3.5]nonan-7-yl)ethenesulfonamide
  • Example 21 1-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,7-diazaspiro[3.5]nonan-2-yl)prop-2-en-1-one WSGR Docket No.62619-716.601 [00484]
  • Example 22 3-(5-Phenyl-3-(4-((2-(vinylsulfonyl)-2,7-diazaspiro[3.5]nonan-7- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00486]
  • Example 23 1-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,8-diazaspiro[4.5]decan-2-yl)prop-2-en-1-one [00488]
  • Example 24 3-(5-Phenyl-3-(4-((2-(vinylsulfonyl)-2,8-diazaspiro[4.5]decan-8- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine WSGR Docket No.62619-716.601 [00490]
  • Example 25 1-(9-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3,9-diazaspiro[5.5]undecan-3-yl)prop-2-en-1-one [00492]
  • Example 26 3-(5-Phenyl-3-(4-((9-(vinylsulfonyl)-3,9-diazaspiro[5.5]undecan-3- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00494]
  • Example 27 1-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,6-diazaspiro[3.4]octan-2-yl)prop-2-en-1-one [00496]
  • Example 28 (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-3-yl)ethenesulfonamide [00498]
  • Example 29 (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)pyrrolidin-3-yl)ethenesulfonamide WSGR Docket No.62619-716.601 [00500]
  • Example 30 1-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,7-diazaspiro[4.4]nonan-2-yl)prop-2-en-1-one [00502]
  • Example 31 3-(5-Phenyl-3-(4-((7-(vinylsulfonyl)-2,7-diazaspiro[4.4]nonan-2- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00504]
  • Example 32 1-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,8-diazaspiro[4.5]decan-8-yl)prop-2-en-1-one [00506]
  • Example 33 3-(5-Phenyl-3-(4-((8-(vinylsulfonyl)-2,8-diazaspiro[4.5]decan-2- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00508]
  • Example 34 1-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,7-diazaspiro[4.5]decan-7-yl)prop-2-en-1-one WSGR Docket No.62619-716.601 [00510]
  • Example 35 3-(5-Phenyl-3-(4-((7-(vinylsulfonyl)-2,7-diazaspiro[4.5]decan-2- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00512]
  • Example 36 1-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)prop-2-en-1-one [00514]
  • Example 37 (R)-1-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonan-2-yl)prop-2-en-1-one [00516]
  • Example 38 1-(9-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,9-diazaspiro[5.5]undecan-2-yl)prop-2-en-1-one [00518]
  • Example 39 1-((2S,6S)-4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,6-dimethylpiperazin-1-yl)prop-2-en-1-one WSGR Docket No.62619-716.601 [00520]
  • Example 40 1-((2R,6R)-4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,6-dimethylpiperazin-1-yl)prop-2-en-1-one [00522]
  • Example 41 (R)-1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2-methylpiperazin-1-yl)prop-2-en-1-one [00524]
  • Example 43 1-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)prop-2-en-1-one [00528]
  • Example 44 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azepan-4-yl)acrylamide [00530]
  • Example 45 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azepan-3-yl)acrylamide [00532]
  • Example 46 1-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-4,7-diazaspiro[2.5]octan-4-yl)prop-2-en-1-one [00534]
  • Example 47 (S)-1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2-methylpiperazin-1-yl)prop-2-en-1-one WSGR Docket No.62619-716.601 [00536] To a solution of Intermediate 33 (45 mg, 94.6 ⁇ mol) in THF (1.5 mL) were added K 2 CO 3 (39.2 mg, 284 ⁇ mol) and acryloyl chloride (9.42 mg, 104 ⁇ mol, 8.49 ⁇ L). The reaction mixture was stirred at 0 °C for 1 hr.
  • Example 48 1-((1S,4S)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)prop-2-en-1-one [00538]
  • Example 49 1-((1R,4R)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.1]heptan-2-yl)prop-2-en-1-one WSGR Docket No.62619-716.601 [00540]
  • Example 50 N-(4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-1,4-oxazepan-6-yl)acrylamide
  • Step 1 tert-Butyl 6-acrylamido-1,4-oxazepane-4-carboxylate
  • TEA 94 mg, 925 ⁇ mol
  • Step 2 N-(1,4-Oxazepan-6-yl)acrylamide
  • Step 3 N-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-1,4-oxazepan-6-yl)acrylamide WSGR Docket No.62619-716.601 [00547] To a solution of Intermediate 4 (120 mg, 291 ⁇ mol) and N-(1,4-oxazepan-6- yl)acrylamide (60 mg, 350 ⁇ mol) in DMF (3 mL) was added NaI (5 mg, 29 ⁇ mol) and K 2 CO 3 (81 mg, 583 ⁇ mol).
  • Example 51 (S)-3-(3-(4-((3-Methyl-4-(vinylsulfonyl)piperazin-1-yl)methyl)phenyl)-5- phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00549]
  • Example 52 3-(5-Phenyl-3-(4-((4-(vinylsulfonyl)-4,7-diazaspiro[2.5]octan-7- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine WSGR Docket No.62619-716.601 [00551]
  • Example 53 1-(5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)prop-2-en-1-one [00553]
  • Example 54 1-((2S,6R)-4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,6-dimethylpiperazin-1-yl)prop-2-en-1-one [00555]
  • Example 55 1-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,6-diazaspiro[3.4]octan-6-yl)prop-2-en-1-one [00557]
  • Example 56 3-(5-Phenyl-3-(4-((6-(vinylsulfonyl)-2,6-diazaspiro[3.4]octan-2- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00559]
  • Example 57 1-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-2,6-diazaspiro[3.5]nonan-6-yl)prop-2-en-1-one [00561]
  • Example 58 and 59 N-((5r, 8r)-2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)-2-azaspiro[4.5]decan-8-yl)acrylamide and N-((5s, 8s)-2-(4- (2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-2- azaspiro[4.5]decan-8-yl)acrylamide [00563]
  • Example 12 was separated by SFC (column: DAICEL CHIRALPAK IG (250 mm * 30 mm, 10 ⁇ m); mobile phase: [CO 2 - ACN/EtOH (0.1% NH 3 H 2 O)]; B%: 60% - 60%, A4; 26 min), N-((5r,
  • Example 60 and 61 (S)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)azepan-4-yl)acrylamide and (R)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5- phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)azepan-4-yl)acrylamide WSGR Docket No.62619-716.601 [00565]
  • Example 44 was separated by SFC (column: DAICEL CHIRALPAK AS (250 mm * 30 mm, 10 ⁇ m); mobile phase: [0.1% NH 3 H 2 O MeOH]; B%: 40% - 40%, A5; 40 min), (S)-N-(1-(4- (2-(2-aminopyridin-3-y
  • MS: m/z 544.4 [M + H] + .
  • Example 62 (S)-1-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)-2,7-diazaspiro[4.4]nonan-2-yl)prop-2-en-1-one [00567]
  • Example 63 (E)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)-4-methoxybut-2-enamide [00569]
  • Example 64 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)methacrylamide
  • CH 2 Cl 2 was stirred at 0 °C for 2 hr.
  • the reaction mixture was diluted with H 2 O (10 mL) and extracted with CH2Cl2 (15 mL ⁇ 2).
  • the combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Example 65 N-(3-(3-(4-((4-Acryloyl-4,7-diazaspiro[2.5]octan-7-yl)methyl)phenyl)-5- phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-yl)acrylamide WSGR Docket No.62619-716.601 [00573]
  • Example 66 and 67 1-((1R,4R)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)-2,5-diazabicyclo[2.2.2]octan-2-yl)prop-2-en-1-one and 1- ((1S,4S)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-2,5- diazabicyclo[2.2.2]octan-2-yl)prop-2-en-1-one [00575]
  • Example 38 was separated by SFC (column: Daicel Chiralpak AD(250 mm * 30 mm, 10 ⁇ m);mobile phase: [ACN/MeOH (0.1% NH 3 H 2 O)]; B%: 40% - 40%, A
  • Example 66: MS: m/z 542.4 [M + H] + .
  • Example 68 1-(4-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)prop-2-en-1-one [00577]
  • Example 69 N-(1-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)acrylamide [00579]
  • Example 70 3-(5-Phenyl-3-(4-((4-(prop-1-en-2-ylsulfonyl)piperazin-1- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine WSGR Docket No.62619-716.601 [00581] 2Cl2 (20 mL) were added 2Cl 2 (20 mL). The mixture was stirred at 0 °C for 3 hr. The reaction mixture was quenched with saturated NaHCO3 (10 mL), diluted with H2O (10 mL), and extracted with CH2Cl2 (20 mL x 3).
  • Example 71 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)prop-1-ene-2-sulfonamide [00583]
  • Example 72 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-methoxyprop-2-en-1-one [00585] purification by prep-HPLC (column: [water (NH 4 HCO 3 ) - ACN]; B%: 36% - 66%, 18 min), 1- (4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperazin-1-yl)- 2-methoxyprop-2-en-1-one (Example 72, 37.3 mg, yield: 21%) was obtained as a light-yellow.
  • Example 73 (E)-1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperazin-1-yl)-4-(dimethylamino)but-2-en-1-one [00587] To a solution of Intermediate 2 (100 mg, 201 ⁇ mol), (E)-4-(dimethylamino)but-2-enoic acid (38.9 mg, 301 ⁇ mol) in DMF (2 mL) were added DIEA (51.9 mg, 401 ⁇ mol) and HATU (84 mg, 221 ⁇ mol).
  • Example 74 (E)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)but-2-enamide [00589] To a solution of Intermediate 3 (100 mg, 195 ⁇ mol) and (E)-but-2-enoyl chloride (40.8 mg, 391 ⁇ mol) in CH 2 Cl 2 (2 mL) was added pyridine (46.3 mg, 586 ⁇ mol) at 0 °C. The mixture was stirred at 0 °C for 1 hr.
  • Example 75 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)prop-2-en-1-one [00591]
  • Example 76 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(cyclohex-1-en-1-yl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)prop-2-en-1-one [00593]
  • Example 77 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3,6-dihydro-2H-pyran-4-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperazin-1-yl)prop-2-en-1-one [00595]
  • Example 78 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)prop-2-en-1-one WSGR Docket No.62619-716.601 [00597]
  • Example 79 3-(3-(4-((4-Acryloylpiperazin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3- yl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00599]
  • Example 80 4-(3-(4-((4-Acryloylpiperazin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3- yl)-3H-imidazo[4,5-b]pyridin-5-yl)benzonitrile [00601]
  • Example 81 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)prop-2-en-1-one [00603]
  • Example 82 6-(3-(4-((4-Acryloylpiperazin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3- yl)-3H-imidazo[4,5-b]pyridin-5-yl)pyridin-2(1H)-one [00605]
  • Example 83 5-(3-(4-((4-Acryloylpiperazin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3- yl)-3H-imidazo[4,5-b]pyridin-5-yl)pyridin-2(1H)-one WSGR Docket No.62619-716.601 [00607]
  • Example 84 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-(3-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperazin-1-yl)prop-2-en-1-one [00609]
  • Example 85 4-(3-(4-((4-Acryloylpiperazin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3- yl)-3H-imidazo[4,5-b]pyridin-5-yl)-1-methylpyridin-2(1H)-one WSGR Docket No.62619-716.601 [00611]
  • Example 86 5-(3-(4-((4-Acryloylpiperazin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3- yl)-3H-imidazo[4,5-b]pyridin-5-yl)-1-methylpyridin-2(1H)-one [00613]
  • Example 87 3-(3-(4-((4-Acryloylpiperazin-1-yl)methyl)phenyl)-2-(2-aminopyridin-3- yl)-3H-imidazo[4,5-b]pyridin-5-yl)pyridin-2(1H)-one [00615]
  • Example 88 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00617]
  • Example 89 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(3,6-dihydro-2H-pyran-4-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00619]
  • Example 89 was prepared in a manner similar to Example 2.
  • Example 90 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(3-fluorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide WSGR Docket No.62619-716.601 [00621] 2Cl2 (10 ml) were added TEA for 2 hr. The resulting mixture was extracted with CH 2 Cl 2 (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Example 91 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(3-chlorophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00623] CH 2 Cl 2 0 °C for 2 hr. The reaction mixture was filtered.
  • Example 92 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(1-methyl-2-oxo-1,2-dihydropyridin- 4-yl)-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00625]
  • Example 93 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(6-oxo-1,6-dihydropyridin-3-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00627]
  • Example 94 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(6-oxo-1,6-dihydropyridin-2-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide WSGR Docket No.62619-716.601 [00629]
  • Example 95 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(2-oxo-1,2-dihydropyridin-3-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00631]
  • Example 96 N-(1-(4-(2-(2-Aminopyridin-3-yl)-6-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)acrylamide WSGR Docket No.62619-716.601 [00633]
  • Example 97 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-methylacrylamide
  • TEA 49.6 mg, 490 ⁇ mol
  • acryloyl chloride 17.8 mg, 196 ⁇ mol
  • Example 98 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-(methyl-d3)acrylamide WSGR Docket No.62619-716.601 [00637] Following the general procedure of Example 97, the reaction of Intermediate 70 (50 mg, 102 ⁇ mol) with acryloyl chloride (11 mg, 122 ⁇ mol) was carried out.
  • Example 99 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(3-cyanophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00639]
  • Example 100 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(cyclohex-1-en-1-yl)-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide WSGR Docket No.62619-716.601 [00641]
  • Example 101 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-cyclohexyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00643]
  • Example 102 N-(1-(4-(2-(2-Aminopyridin-3-yl)-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-methylacrylamide
  • Intermediate 75 200 mg, 537 ⁇ mol
  • Intermediate 74 152 mg, 537 ⁇ mol
  • NaI 40.3 mg, 269 ⁇ mol
  • K 2 CO 3 371 mg, 2.69 mmol
  • Example 103 (S)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-3-yl)ethenesulfonamide [00647]
  • Example 104 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azetidin-3-yl)ethenesulfonamide [00649]
  • Example 104 (S)-N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)pyrrolidin-3-yl)ethenesulfonamide [00651]
  • Example 106 3-(5-Phenyl-3-(4-((2-(vinylsulfonyl)-2,6-diazaspiro[3.4]octan-6- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00653] To a solution of Intermediate 19 (50 mg, 102 ⁇ mol) and TEA (52 mg, 513 ⁇ mol) in CH 2 Cl 2 (10 mL) was added dropwise a solution of 2-chloroethane-1-sulfonyl chloride (20 mg, 123 ⁇ mol) in CH2Cl2 (5 mL) at 0 °C.
  • reaction mixture was stirred at 0 °C for 0.5 hr.
  • the reaction mixture was quenched with saturated NaHCO 3 (aq) (10 mL) at 0 °C and extracted with CH 2 Cl 2 (20 mL x 2).
  • the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 107 (S)-3-(5-Phenyl-3-(4-((7-(vinylsulfonyl)-2,7-diazaspiro[4.4]nonan-2- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00655] To a solution of Intermediate 41 (50 mg, 100 ⁇ mol) and TEA (50 mg, 498 ⁇ mol) in CH2Cl2 (10 mL) was added dropwise a solution of 2-chloroethane-1-sulfonyl chloride (21 mg, 130 ⁇ mol) in CH2Cl2 (5 mL) at 0 °C.
  • reaction mixture was stirred at 0 °C for 0.5 hr.
  • the reaction mixture was quenched with saturated NaHCO3 (aq) (10 mL) at 0 °C and extracted with CH2Cl2 (20 mL x 2).
  • the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure to give a residue.
  • Example 108 3-(5-Phenyl-3-(4-((6-(vinylsulfonyl)-2,6-diazaspiro[3.3]heptan-2- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00657] To a solution of Intermediate 5 (70 mg, 148 ⁇ mol) and TEA (75 mg, 739 ⁇ mol) in CH2Cl2 (10 mL) was added dropwise a solution of 2-chloroethane-1-sulfonyl chloride (31 mg, 192 WSGR Docket No.62619-716.601 ⁇ mol) in CH2Cl2 (5 mL) at 0 °C.
  • reaction mixture was stirred at 0 °C for 0.5 hr.
  • the reaction mixture was quenched with saturated NaHCO 3 (aq) (10 mL) at 0 °C and extracted with CH 2 Cl 2 (20 mL x 2).
  • the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 109 3-(5-Phenyl-3-(4-(((1R,4R)-5-(vinylsulfonyl)-2,5- diazabicyclo[2.2.1]heptan-2-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00659] To a solution of Intermediate 36 (70 mg, 148 ⁇ mol) and TEA (75 mg, 739 ⁇ mol) in CH2Cl2 (10 mL) was added dropwise a solution of 2-chloroethane-1-sulfonyl chloride (31 mg, 192 ⁇ mol) in CH 2 Cl 2 (5 mL) at 0 °C.
  • reaction mixture was stirred at 0 °C for 0.5 hr.
  • the reaction mixture was quenched with saturated NaHCO 3 (aq) (10 mL) at 0 °C and extracted with CH 2 Cl 2 (20 mL x 2).
  • the combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Example 110 3-(5-Phenyl-3-(4-((5-(vinylsulfonyl)-2,5-diazabicyclo[2.2.2]octan-2- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00661]
  • Example 111 N-(7-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-7-azaspiro[3.5]nonan-2-yl)ethenesulfonamide
  • 2-chloroethane-1-sulfonyl chloride 38 mg, 235 ⁇ mol
  • the resulting mixture was stirred at 0 °C for 16 hr.
  • the reaction mixture was quenched with saturated NaHCO 3 (10 mL) at 0 °C and extracted with CH 2 Cl 2 (20 mL x 2).
  • the combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Example 112 3-(5-Phenyl-3-(4-((4-(vinylsulfonyl)-1,4-diazepan-1-yl)methyl)phenyl)- 3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00665]
  • Example 113 & 114 N-((5r,8r)-2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)-2-azaspiro[4.5]decan-8-yl)ethenesulfonamide & N-((5s,8s)- 2-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3-yl)benzyl)-2- azaspiro[4.5]decan-8-yl)ethenesulfonamide [00667] To a solution of Intermediate 8 (50 mg, 94 ⁇ mol) and TEA (48 mg, 472 ⁇ mol) in CH 2 Cl 2 (10 mL) was added dropwise a solution of 2-chloroethane-1-sulfonyl chloride (15 mg, 94.4
  • reaction mixture was stirred at 0 °C for 1 hr.
  • the reaction mixture was quenched with NaHCO 3 (aq) (10 mL) at 0 °C and extracted with CH 2 Cl 2 (20 mL x 2).
  • the combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Example 115 3-(5-Phenyl-3-(4-((2-(prop-1-en-2-ylsulfonyl)-2,7-diazaspiro[3.5]nonan- 7-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00669] 2Cl2 (40 mL) was added DIEA CH 2 Cl 2 (5 mL) was added at 0 °C. The mixture was stirred at 0 °C for 5 hr.
  • Example 116 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)-2-fluoroprop-2-en-1-one [00671] To a solution of Intermediate 2 (150 mg, 260 mmol) and TEA (52.6 mg, 519 mmol) in DMF (3 mL) were added 2-fluoroacrylic acid (30.4 mg, 338 mmol), EDCI (74.8 mg, 389 mmol) and DMAP (3.18 mg, 26.0 mmol). The mixture was stirred at 25 °C for 4 hr.
  • Example 118 (R)-3-(3-(4-((3-Methyl-4-(vinylsulfonyl)piperazin-1-yl)methyl)phenyl)-5- phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00675]
  • Example 119 3-(5-Phenyl-3-(4-(((1S,4S)-5-(vinylsulfonyl)-2,5- diazabicyclo[2.2.1]heptan-2-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00677]
  • Example 120 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00679]
  • Example 121 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-(4-cyanophenyl)-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide [00681] CH 2 Cl 2 mixture was stirred at 0 °C for 2 hr. The reaction mixture was concentrated under reduced pressure.
  • Example 122 N-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)acrylamide
  • 2 Cl 2 (3 mL) were was stirred at 0 °C for 0.5 hr. The mixture was quenched with water (10 mL) at 0 °C and extracted with EtOAc (20 mL x 3). The combined organic layers were washed with brine (30 mL), dried over anhydrous Na 2 SO 4 , filtered and concentrated.
  • Example 123 1-((3aR,6aS)-5-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-2-en-1-one [00685] To a solution of Intermediate 77 (100 mg, 205 mol) in CH2Cl2 (1 mL) were added TEA (62.0 mg, 615 mol) and acryloyl chloride (19.0 mg, 205 mol). The mixture was stirred at 0 °C for 1 hr. The reaction was concentrated.
  • Example 124 3-(3-(4-(((3R,5R)-3,5-Dimethyl-4-(vinylsulfonyl)piperazin-1- yl)methyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00687]
  • Example 125 3-(3-(4-(((3S,5R)-3,5-Dimethyl-4-(vinylsulfonyl)piperazin-1- yl)methyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00689]
  • Example 126 3-(3-(4-(((3S,5S)-3,5-Dimethyl-4-(vinylsulfonyl)piperazin-1- yl)methyl)phenyl)-5-phenyl-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00691]
  • Example 127 3-(5-Phenyl-3-(4- ((8-(vinylsulfonyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)methyl)phenyl)-3H-imidazo[4,5- b]pyridin-2-yl)pyridin-2-amine [00693]
  • Example 128 3-(5-Phenyl-3-(4-((3-(vinylsulfonyl)-3,8-diazabicyclo[3.2.1]octan-8- yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine WSGR Docket No.62619-716.601 [00695] To a solution of Intermediate 30 (60 mg, 123 ⁇ mol) and TEA (62 mg, 615 ⁇ mol123 ⁇ mol) in CH2Cl2 (10 mL) was added dropwise a solution of 2-chloroethane-1-sulfonyl chloride (26 mg, 160 ⁇ mol) in CH2Cl2 (5 mL) at 0 °C.
  • reaction mixture was stirred at 0 °C for 1 hr.
  • the reaction mixture was quenched with saturated NaHCO 3 (aq) (10 mL) at 0 °C and extracted with CH2Cl2 (20 mL x 2).
  • the combined organic layers were washed with brine (50 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 129 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azepan-3-yl)ethenesulfonamide [00697]
  • Example 130 3-(5-Phenyl-3-(4-(((3aR,6aS)-5-(vinylsulfonyl)hexahydropyrrolo[3,4- c]pyrrol-2(1H)-yl)methyl)phenyl)-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00699]
  • Example 131 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-ethylacrylamide
  • CH 2 Cl 2 5 mL was added Et 3 25 °C for 1 hr.
  • the reaction mixture was poured into H2O (20 mL).
  • the aqueous phase was extracted with CH 2 Cl 2 (20 mL x 2).
  • the combined organic layers were washed with brine (20 mL x 2), dried over anhydrous Na 2 SO 4 , filtered and concentrated.
  • the mixture was stirred at 25 °C for 16 hr.
  • the reaction mixture was diluted with H2O (30 mL) and extracted with EtOAc (30 mL x 2). The combined organic layers were washed with brine (50 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Step 2 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-(cyanomethyl)acrylamide
  • the mixture was added H2O (5 mL) and extracted with EtOAc (10 mL x 2).
  • Example 133 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)-N-cyclopropylacrylamide
  • H 2 O 5 mL
  • CH 2 Cl 2 10 mL
  • CH2Cl2 15 mL x 2
  • the combined organic layers were washed with brine (15 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • Example 134 N-allyl-N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)acrylamide
  • Step 1 3-(3-(4-((4-(Allylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
  • WSGR Docket No.62619-716.601 [00711] 2CO 3 stirred at 25 °C for 16 hr. The mixture was filtered.
  • Step 2 N-allyl-N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)acrylamide
  • the mixture was quenched with H2O (10 mL), and then extracted with CH2Cl2 (15 mL x 2).
  • Example 135 1-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-1,5-dihydro-2H-pyrrol-2-one WSGR Docket No.62619-716.601 [00715] 2Cl2 (100 mL) was added Ti(Oi-Pr) 4 2 Cl 2 (20 mL). The mixture was stirred at 25 °C for 0.5 hr under N 2 2 Cl 2 (20 mL) was added into the mixture, and the reaction mixture was stirred at 40 °C for 16 hr under N2 atmosphere.
  • Example 136 N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-(but-3-en-1-yl)acrylamide
  • Step 1 3-(3-(4-((4-(But-3-en-1-ylamino)piperidin-1-yl)methyl)phenyl)-5-phenyl-3H- imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine
  • 2CO3 at 25 °C for 12 hr, and then stirred at 60 °C for 12 hr.
  • Step 2 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-(but-3-en-1-yl)acrylamide
  • 3-(3-(4-((4-(but-3-en-1-ylamino)piperidin-1-yl)methyl)phenyl)-5- phenyl-3H was stirred at 0 °C for 1 hr. The mixture was quenched with H2O (10 mL) and extracted with CH 2 Cl 2 (15 mL x 2).
  • Example 137 1-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-5,6-dihydropyridin-2(1H)-one
  • 2 Cl 2 (30 mL) was added Ti(Oi- Pr)4 2Cl2 (100 mL). The mixture was stirred at 25 °C for 0.5 hr under N 2 2 Cl 2 (20 mL) was added into the mixture, and the reaction mixture was stirred at 40 °C for 16 hr under N 2 atmosphere.
  • Example 138 N-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperazin-1-yl)-N-methylacrylamide [00724] 2 Cl 2 (1 mL) were stirred at 25 °C for 2 hr. The mixture was concentrated.
  • Example 139 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-methyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)acrylamide WSGR Docket No.62619-716.601 [00726]
  • Example 140 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)-N-methylacrylamide [00728]
  • Example 141 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-cyclopropyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)-N-methylacrylamide
  • 2CO 3 503 mg, 3.64 mmol.
  • the mixture was stirred at 50 °C for 2 hr.
  • the resulting mixture was extracted with EtOAc (20 mL x WSGR Docket No.62619-716.601 3).
  • the combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Example 142 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)-N-(methyl-d3)acrylamide
  • Step 1 tert-Butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)piperidin-4-yl)(methyl-d 3 )carbamate
  • Step 2 3-(3-(4-((4-((Methyl-d 3 )amino)piperidin-1-yl)methyl)phenyl)-5-morpholino- 3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine [00735] To a mixture of tert-butyl (1-(4-(2-(2-aminopyridin-3-yl)-5-morpholino-3H- imidazo[4,5-b]pyridin-3-yl)benzyl)piperidin-4-yl)(methyl-d 3 )carbamate (700 mg, 1.16 mmol) in CH2Cl2 (10 mL) was added HCl/1,4-dioxane (4 M, 5 mL), then the mixture was stirred at 20 °C for 2 hr.
  • the reaction mixture was diluted with H2O (50 mL) and extracted with CH2Cl2 (20 mL x 3).
  • the aqueous phase was neutralized by addition saturated NaHCO 3 (100 mL), and then extracted with CH2Cl2 (50 mL x 6).
  • the combined organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure, 3-(3-(4-((4-((methyl-d3)amino)piperidin-1- yl)methyl)phenyl)-5-morpholino-3H-imidazo[4,5-b]pyridin-2-yl)pyridin-2-amine (518.8 mg, yield: 82%) was obtained as a white powder.
  • Step 3 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-morpholino-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperidin-4-yl)-N-(methyl-d3)acrylamide
  • reaction mixture was quenched with H2O (30 mL) at 0 °C and extracted with CH2Cl2 (20 mL x 3). The combined organic layers were washed with H2O (30 mL x 2), dried over Na2SO4, filtered and concentrated under reduced pressure.
  • Example 143 1-(2-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,7-diazaspiro[3.5]nonan-7-yl)but-2-yn-1-one [00739] To a solution of Intermediate 23 (80 mg, 159 mmol) and TEA (32.3 mg, 319 mmol) in DMF (1.0 mL) were added but-2-ynoic acid (17.4 mg, 207 mmol), EDCI (45.9 mg, 239 mmol) and DMAP (1.95 mg, 15.9 mmol).
  • Example 144 1-((3aR,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)prop-2-yn-1-one [00741] 2 Cl 2 (1 mL) were added concentrated.
  • Example 145 1-((3aR,6aS)-5-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5- b]pyridin-3-yl)benzyl)hexahydropyrrolo[3,4-c]pyrrol-2(1H)-yl)but-2-yn-1-one [00743]
  • Example 146 N-(4-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)propiolamide [00745] To a solution of 2,4,6-tributyl-1,3,5,2,4,6-trioxatriphosphinane 2,4,6-trioxide (421 mg, 1.17 mmol) in CH2Cl2 (1 mL) and EtOAc (1 mL) were added Intermediate 76 (200 mg, 390 This mixture was stirred at 0 °C for 30 mins. The mixture was concentrated.
  • Example 147 N-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)piperazin-1-yl)but-2-ynamide [00747] filtered and concentrated under reduced pressure.
  • Example 148 N-(1-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperidin-4-yl)but-2-ynamide
  • Intermediate 3 150 mg, 293 mmol
  • TEA 59.3 mg, 586 mmol
  • DMF 1.5 mL
  • Example 149 1-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)prop-2-yn-1-one [00751] concentrated under reduced pressure.
  • Example 150 1-(8-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)-3,8-diazabicyclo[3.2.1]octan-3-yl)but-2-yn-1-one [00753] WSGR Docket No.62619-716.601 concentrated under reduced pressure.
  • Example 151 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperazin-1-yl)but-2-yn-1-one [00755] filtered and concentrated under reduced pressure.
  • Example 152 1-(6-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)-2,6-diazaspiro[3.3]heptan-2-yl)but-2-yn-1-one WSGR Docket No.62619-716.601 [00757] To a solution of Intermediate 5 (100 mg, 293 mmol, HCl salt) and DIEA (109 mg, 845 mmol) in DMF (2.0 mL) were added but-2-ynoic acid (19.5 mg, 232 mmol), EDCI (60.7 mg, 317 mmol) and HOBt (42.8 mg, 317 mmol).
  • Example 153 N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azetidin-3-yl)but-2-ynamide
  • DMF was filtered and purified by prep-HPLC (column: [water (NH 4 HCO 3 ) - ACN]; B%: 27% - 57%, 18 min), N-(1-(4-(2-(2-aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin-3- yl)benzyl)azetidin-3-yl)but-2-ynamide (Example 153, 39.9 mg, yield: 33%) was obtained as a yellow solid.
  • Example 154 1-(4-(4-(2-(2-Aminopyridin-3-yl)-5-phenyl-3H-imidazo[4,5-b]pyridin- 3-yl)benzyl)piperazin-1-yl)prop-2-yn-1-one WSGR Docket No.62619-716.601 [00761] was stirred at 25 °C for 16 hr. The reaction mixture was diluted with H 2 O (5 mL) and extracted with EtOAc (10 mL x 3). The combined organic layers were washed with brine (30 mL), dried over Na 2 SO 4 , filtered and concentrated under reduced pressure.
  • NanoBRET Target Engagement (TE) Assay is a highly specific and validated cell-based technique for assessing target engagement (Vasta et al., 2018, Cell Chem Biol.25(2):206-214).
  • the NanoBRET Target Engagement (TE) Intracellular Kinase Assays are based on the NanoBRET System (Promega Corporation), an energy transfer technique designed to measure molecular proximity in living cells.
  • the NanoBRET TE Assays measure the apparent affinity of test compounds by competitive displacement of the NanoBRET tracer compound, which is a cell permeable molecule engineered to be reversibly bound to a NanoLuc® luciferase-kinase fusion expressed in cells.
  • NanoBRET assay procedure was used to interrogate the compounds against the full length AKT E17K per manufacturers WSGR Docket No.62619-716.601 suggestions. Briefly, HEK-293 cells (ATCC Cat # CRL-1573) were used for transfection purposes using FuGENE HD Transfection Reagent (Promega Cat # E2311). All cells were evaluated for viability prior to transfection and optimization of the transfection was done prior to experimentation. Greater than 95% viability was used for all experiments. Following transfection, cells were washed and resuspended in Opti-MEM. NanoBRET assays were performed in white, 384-well plates (Corning) at a density of 2x10 5 cells/well.
  • All example compounds were prepared as concentrated stock solutions in DMSO (Sigma-Aldrich). Compounds are dissolved in DMSO to make 10 mM stock solution. Example compounds were transferred as 40uL of 10 mM stock solution to a 384 pp-plate (LABCYTE, PP-0200) and Apricot liquid handler. A Labcyte ECHO 550 compound dispenser was used to facilitate compound transfer directly to cells. Cells were equilibrated for 2 hr with energy transfer probes and example compound prior to BRET measurements.
  • AKTE17K Promega Cat # NV2421
  • specific probe NaBRET tracer, Promega Cat # N264B
  • tracer dilution buffer 12.5 mM HEPES, 31.25% PEG-400, pH 7.5.
  • the energy transfer probes were added to the cells at concentrations optimized for the target in question (AKT E17K).
  • NanoBRET NanoGlo Substrate Promega Cat # N157D
  • Extracellular Nanoluc Inhibitor Promega Cat # N235C
  • luminescence was measured on Envision Reader (Perkin Elmer) Multimode Luminometer equipped with 450nmBPfilter (donor)and 600nmLPfilter (acceptor), using 0.5 s integration time.
  • Milli-BRET units mBU
  • Apparent tracer affinity values EC50
  • Competitive displacement data were then plotted and data were fit to determine the EC50 value for each example compound. Table 2 provides the assay results for select examples.
  • Activity is defined as “+”, for EC 50 greater 600 nanomolar; “++” for EC 50 between 60-600 nanomolar; “+++” for EC50 between 15-60 nanomolar; and “++++”, for EC50 less than 15 nanomolar.
  • Table 2 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No.62619-716.601 WSGR Docket No
  • Example 1 Oral capsule
  • the active ingredient is a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof.
  • a capsule for oral administration is prepared by mixing 1-1000 mg of active ingredient with starch or other suitable powder blend. The mixture is incorporated into an oral dosage unit such as a hard gelatin capsule, which is suitable for oral administration.
  • Example 2 Solution for injection
  • the active ingredient is a compound of Table 1, or a pharmaceutically acceptable salt or solvate thereof, and is formulated as a solution in sesame oil at a concentration of 50 mg- eq/mL.
  • the examples and embodiments described herein are for illustrative purposes only and various modifications or changes suggested to persons skilled in the art are to be included within the spirit and purview of this application and scope of the appended claims.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des inhibiteurs de AKT1, des compositions pharmaceutiques comprenant les composés inhibiteurs, et des procédés d'utilisation des composés inhibiteurs de AKT1 pour le traitement d'une maladie.
PCT/US2023/078714 2022-11-09 2023-11-03 Modulateurs de akt1 WO2024102621A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202263383008P 2022-11-09 2022-11-09
US63/383,008 2022-11-09

Publications (1)

Publication Number Publication Date
WO2024102621A1 true WO2024102621A1 (fr) 2024-05-16

Family

ID=91033539

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2023/078714 WO2024102621A1 (fr) 2022-11-09 2023-11-03 Modulateurs de akt1

Country Status (1)

Country Link
WO (1) WO2024102621A1 (fr)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011082270A2 (fr) * 2009-12-30 2011-07-07 Arqule. Inc. Composés imidazopyridinyl-aminopyridine substitués
AU2021351093A1 (en) * 2020-09-30 2023-06-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compound as akt kinase inhibitor
WO2023168291A1 (fr) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Modificateurs covalents de akt1 et leurs utilisations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011082270A2 (fr) * 2009-12-30 2011-07-07 Arqule. Inc. Composés imidazopyridinyl-aminopyridine substitués
AU2021351093A1 (en) * 2020-09-30 2023-06-01 Chia Tai Tianqing Pharmaceutical Group Co., Ltd. Compound as akt kinase inhibitor
WO2023168291A1 (fr) * 2022-03-02 2023-09-07 Terremoto Biosciences, Inc. Modificateurs covalents de akt1 et leurs utilisations

Non-Patent Citations (16)

* Cited by examiner, † Cited by third party
Title
DATABASE CAS 18 March 2007 (2007-03-18), ANONYMOUS, XP093174542, Database accession no. 927128-48-1 *
DATABASE CAS 20 March 2007 (2007-03-20), ANONYMOUS, XP093174521, Database accession no. 927586-34-3 *
DATABASE CAS 23 March 2018 (2018-03-23), ANONYMOUS, XP093174512, Database accession no. 2197476-83-6 *
DATABASE CAS 6 September 2017 (2017-09-06), ANONYMOUS, XP093174518, Database accession no. 2125614-68-6 *
DATABASE CAS Registry 18 March 2007 (2007-03-18), ANONYMOUS, XP093174545, Database accession no. 927109-87-3 *
DATABASE CAS Registry 18 March 2007 (2007-03-18), ANONYMOUS, XP093174546, Database accession no. 927072-22-8 *
DATABASE CAS Registry 18 March 2007 (2007-03-18), ANONYMOUS, XP093174549, Database accession no. 927072-01-3 *
DATABASE CAS Registry 18 March 2007 (2007-03-18), ANONYMOUS, XP093174554, Database accession no. 927054-54-4 *
DATABASE CAS Registry 18 March 2007 (2007-03-18), ANONYMOUS, XP093174557, Database accession no. 927054-52-2 *
DATABASE CAS Registry 18 March 2007 (2007-03-18), ANONYMOUS, XP093174560, Database accession no. 927054-46-4 *
DATABASE CAS Registry 20 March 2007 (2007-03-20), ANONYMOUS, XP093174531, Database accession no. 927586-26-3 *
DATABASE CAS Registry 20 March 2007 (2007-03-20), ANONYMOUS, XP093174536, Database accession no. 927552-56-5 *
DATABASE CAS Registry 20 March 2007 (2007-03-20), ANONYMOUS, XP093174539, Database accession no. 927546-89-2 *
DATABASE CAS REGISTRY 23 March 2018 (2018-03-23), ANONYMOUS, XP093174576, Database accession no. 2197891-41-9 *
DATABASE CAS Registry 30 July 2007 (2007-07-30), ANONYMOUS, XP093174527, Database accession no. 927586-40-1 *
DATABASE CAS Registry Number 18 March 2007 (2007-03-18), ANONYMOUS, XP093174551, Database accession no. 927054-96-4 *

Similar Documents

Publication Publication Date Title
US10385051B2 (en) Inhibitors of lysine specific demethylase-1
US10543198B2 (en) Inhibitor of lysine specific demethylase-1
US11098031B1 (en) Inhibitors of RAF kinases
AU2020244761A1 (en) Inhibitors of RAF kinases
WO2015110999A1 (fr) Inhibiteurs de ezh2 et leurs utilisations
US11407737B2 (en) Inhibitors of RAF kinases
EP2718293A1 (fr) Pyridopyrazines substituées en tant que nouveaux inhibiteurs de syk
AU2020268814A1 (en) Inhibitors of RAF kinases
EP4327877A2 (fr) Inhibiteurs doubles de l'atm et de l'adn-pk destinés à être utilisés dans une thérapie antitumorale
WO2022081469A1 (fr) Inhibiteurs de kinases raf
EP3787629A1 (fr) Inhibiteurs de kinases dépendantes des cyclines
AU2021285974A1 (en) Inhibitors of fibroblast growth factor receptor kinases
JP2019530740A (ja) ピリジン並びに５員芳香環系化合物、その製造方法及び使用
WO2024102621A1 (fr) Modulateurs de akt1
WO2024064026A1 (fr) Modulateurs d'akt1
WO2024107565A1 (fr) Modulateurs de akt1
WO2024054512A1 (fr) Modulateurs de akt1
US11814384B2 (en) Inhibtors of Raf kinases
WO2024073371A1 (fr) Modulateurs d'akt1
WO2023224998A1 (fr) Inhibiteurs de parg

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 23889534

Country of ref document: EP

Kind code of ref document: A1